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ABSTRACT 
 
The Diabetic Heart: Examination of the Inner Mitochondrial Membrane  
 
Tara L. Croston 
 
Cardiovascular complications, such as diabetic cardiomyopathy, are the primary 
cause of morbidity and mortality in patients with diabetes mellitus. The hyperglycemic 
environment associated with diabetes mellitus has been shown to induce the 
mitochondrial dysfunction contributing to diabetic cardiomyopathy. The examination of 
mitochondrial function is further complicated by the existence of two spatially and 
functionally distinct cardiac mitochondrial subpopulations, the subsarcolemmal (SSM) 
interfibrillar (IFM) mitochondria. These two pools of mitochondria respond differently to 
pathologic stimuli, such as diabetes mellitus. Targeted by the deleterious effects of 
diabetes mellitus, the inner mitochondrial membrane (IMM) is composed of a specific 
lipid environment that houses many critical processes and machinery required for 
proper mitochondrial function. The impact of diabetes mellitus on the IMM, including the 
lipids and processes housed within, is not completely understood in type 1 diabetic 
setting, and has not been assessed in mitochondrial subpopulations from type 2 
diabetic human heart. The goal of the studies included in this dissertation was to 
understand the importance of IMM preservation during diabetes mellitus and to translate 
rodent mitochondrial dysfunction that occurs during diabetic cardiomyopathy to the 
human diabetic heart. FVB mice (20-25 grams) were made type 1 diabetic through 
multiple low dose injections of streptozotocin (STZ) for five consecutive days. Five 
weeks post diabetic onset, hearts were excised and mitochondrial subpopulations were 
isolated. For the type 2 diabetic human population, right atrial appendages were excised 
during coronary artery bypass grafting or valve replacement surgery, from which 
mitochondrial subpopulations were isolated. Cardiolipin, an essential phospholipid 
contained within the IMM, was shown to be decreased during a type 1 diabetic insult; 
however the mechanism attributing to this decrease in unknown; therefore, the 
cardiolipin biosynthetic pathway was evaluated in the type 1 diabetic mouse model. 
Results indicated decreased cardiolipin synthase protein content and activity in the 
diabetic IFM. The data also revealed a decrease in two critical cardiolipin-ATP synthase 
associations, which could potentially contribute to the observed decreased ATP 
synthase activity in the diabetic IFM, all of which are located in the IMM. Within the type 
1 diabetic mouse model, a key constituent involved in protein import, glucose regulated 
protein 75, has been reported to be decreased and when overexpressed, preliminary 
data depicted mitochondrial functional restoration in the diabetic IFM. Mitochondrial 
dysfunction, as evidenced by decreased state 3 mitochondrial respiration, as well as 
decreased electron transport chain complex I and complex IV activity was observed in 
the SSM of type 2 diabetic human heart, compared to the non-diabetic heart. These 
results suggest for the first time, that mitochondrial dysfunction is present in the type 2 
diabetic human heart and that SSM impacted to a greater extent than IFM. Taken 
together, the results of these studies demonstrate the importance of preserving the IMM 
structure to alleviate mitochondrial dysfunction associated with the diabetic heart, as 
well as understanding the effect of diabetes mellitus on human cardiac mitochondrial 
subpopulations. Further, the preliminary results highlight therapeutic strategies involving 
protein import constituents on the ability to attenuate mitochondrial dysfunction that 
occurred during a diabetic insult. 
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SPECIFIC AIMS 
 
Cardiovascular complications, such as diabetic cardiomyopathy, are the primary 
cause of heart failure in patients with diabetes mellitus (3). The hyperglycemic 
environment produced during diabetes mellitus contributes to diabetic-associated 
mitochondrial dysfunction (8, 9). A critical component in the mitochondrion is the inner 
mitochondrial membrane (IMM) which contains a signature lipid environment required 
for proper mitochondrial function. Cardiac mitochondria consist of two spatially distinct 
subpopulations: subsarcolemmal mitochondria (SSM) and interfibrillar mitochondria 
(IFM), of which no group has currently examined in the diabetic human heart.  
 
Cardiolipin, an integral phospholipid located in the IMM, has been shown to play 
a vital role in mitochondrial bioenergetics (1). We have previously observed decreased 
cardiolipin content during a type 1 diabetic insult (6), specifically in IFM (5); however, 
the mechanisms underlying this loss are unknown. Proteomic data indicates decreased 
abundance of mitochondrial proteins in the diabetic heart, which include IMM proteins 
(2, 7), such as electron transport chain (ETC) proteins associated with cardiolipin. Our 
laboratory has suggested a correlation between the proteomic decrements to a 
decrease in nuclear-encoded protein import into the mitochondria during a type 1 
diabetic insult (2). Mitochondrial glucose regulated protein 75 (Grp75), an essential 
component of nuclear-encoded protein import, was also decreased in diabetes mellitus 
(2, 4). Currently, the mechanisms contributing to cardiolipin loss and the therapeutic 
benefit of molecular gene manipulation on a key mitochondrial protein import constituent 
during diabetes mellitus are currently unclear.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
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Our long term goal is to understand the importance of IMM preservation during 
diabetes mellitus and to translate rodent mitochondrial dysfunction that occurs during 
diabetic cardiomyopathy to the human diabetic heart. The objectives of this 
dissertation were to: (1) to determine how the cardiolipin biosynthesis pathway and 
cardiolipin-protein interactions are impacted by type 1 diabetes mellitus; (2) to 
determine the therapeutic value of mitochondrial Grp75 overexpression on 
mitochondrial protein import during a type 1 diabetic insult; and (3) to examine how 
mitochondrial subpopulations in the human heart are affected by diabetes mellitus. The 
central hypothesis of this dissertation was that the mitochondrion is negatively 
impacted by diabetes mellitus, leading to deleterious effects to the IMM and 
compromising the proteins associated with cardiolipin and protein import, which will 
translate to the diabetic human heart. The central hypothesis of this study will be 
examined by testing the following Specific Aims: 
 
Specific Aim I: Determine the effect of a type 1 diabetic insult on the biosynthesis of 
cardiolipin, and evaluate key cardiolipin -protein interactions in the IMM. Further, 
determine if the effect is mitochondrial-subpopulation specific.  
Our working hypothesis is that type 1 diabetes mellitus decreases cardiolipin 
content, due to deficient cardiolipin synthase, and that this lack of cardiolipin decreases 
its association with vital proteins in the IMM, specifically ATP synthase. Further, these 
effects will be most pronounced in IFM. 
 
xvii 
 
Specific Aim II: Examine the therapeutic value of Grp75 overexpression on 
mitochondrial function following a type 1 diabetic insult. Further, determine if the effect 
is mitochondrial-subpopulation specific.  
A novel transgenic mouse model created in our laboratory will be used to 
examine the role of Grp75 during diabetes mellitus. Our working hypothesis is that 
Grp75 overexpression will preserve mitochondrial function through a mechanism of 
enhanced protein import during a type 1 diabetic insult. These effects will be most 
pronounced in IFM. 
 
Specific Aim III: Evaluate mitochondrial dysfunction in human heart tissue and 
examine the effects of diabetes mellitus on mitochondrial subpopulations.  
Our working hypothesis is that diabetes mellitus causes abnormalities in 
mitochondria, characterized by decreased size, function and protein import. The 
decreased protein import potentially leads to mitochondrial proteome decrements and 
ultimately resulting in mitochondrial dysfunction associated with diabetes mellitus. 
 
Our rationale for the research conducted for this dissertation is based on the 
importance of preserving the IMM structure to alleviate mitochondrial dysfunction 
associated with the diabetic heart, as well as understanding the effect of diabetes 
mellitus on human cardiac mitochondrial subpopulations. The anticipated outcomes 
were intended to highlight therapeutic strategies involving cardiolipin synthesis and 
protein import on the ability to attenuate mitochondrial dysfunction that occurred during 
a diabetic insult.  The research gathered from this dissertation was innovative because 
xviii 
 
the mechanisms elucidating mitochondrial dysfunction during a diabetic insult have not 
been previously examined, especially in a translational model, and several of the 
methodologies utilized were developed in our laboratory. At the completion of this 
dissertation, we were able to highlight potential at-risk targets within the IMM during a 
diabetic insult and determine the therapeutic benefit of overexpressing a key constituent 
in the protein import machinery. The results gathered has advanced our understanding 
of the mechanisms involved in both type 1 and type 2 models, from which therapeutic 
strategies can be developed. 
  
xix 
 
REFERENCES 
 
1. Acehan D, Malhotra A, Xu Y, Ren M, Stokes DL, and Schlame M. Cardiolipin 
affects the supramolecular organization of ATP synthase in mitochondria. Biophys J 
100: 2184-2192, 2011. 
2. Baseler WA, Dabkowski ER, Williamson CL, Croston TL, Thapa D, Powell 
MJ, Razunguzwa TT, and Hollander JM. Proteomic alterations of distinct 
mitochondrial subpopulations in the type 1 diabetic heart: contribution of protein import 
dysfunction. Am J Physiol Regul Integr Comp Physiol 300: R186-200, 2011. 
3. Cai L, Li W, Wang G, Guo L, Jiang Y, and Kang YJ. Hyperglycemia-Induced 
Apoptosis in Mouse Myocardium. Diabetes 51: 1938-1948, 2002. 
4. Dabkowski ER, Baseler WA, Williamson CL, Powell M, Razunguzwa TT, 
Frisbee JC, and Hollander JM. Mitochondrial dysfunction in the type 2 diabetic heart is 
associated with alterations in spatially distinct mitochondrial proteomes. Am J Physiol 
Heart Circ Physiol 299: H529-540, 2010. 
5. Dabkowski ER, Williamson CL, Bukowski VC, Chapman RS, Leonard SS, 
Peer CJ, Callery PS, and Hollander JM. Diabetic cardiomyopathy-associated 
dysfunction in spatially distinct mitochondrial subpopulations. Am J Physiol Heart Circ 
Physiol 296: H359-369, 2009. 
6. Han X, Yang J, Cheng H, Yang K, Abendschein DR, and Gross RW. Shotgun 
lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered 
substrate utilization with mitochondrial dysfunction. Biochemistry 44: 16684-16694, 
2005. 
xx 
 
7. Hollander JM, Baseler WA, and Dabkowski ER. Proteomic remodeling of 
mitochondria in heart failure. Congest Heart Fail 17: 262-268, 2011. 
8. Rolo AP and Palmeira CM. Diabetes and mitochondrial function: Role of 
hyperglycemia and oxidative stress. Toxicology and Applied Pharmacology 212: 167-
178, 2006. 
9. Shen X, Zheng S, Thongboonkerd V, Xu M, Pierce WM, Jr., Klein JB, and 
Epstein PN. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 
diabetes. Am J Physiol Endocrinol Metab 287: E896-905, 2004. 
 
 
 
  
Chapter 1: 
Literature Review 
  
2 
 
1.1 Diabetes Mellitus 
 
Diabetes mellitus is a metabolic disease characterized by high blood glucose 
levels and insulin deficiency. There are different types of diabetes mellitus, all of which 
result in a hyperglycemic environment; however, they manifest differently. Type 1 and 
type 2 are the more common forms of diabetes mellitus. A third form, called gestational 
diabetes, occurs in pregnant women who have high blood glucose levels during 
pregnancy (4). Other types of diabetes mellitus due to other causes also exists, such as 
genetic defects in β-cell function and insulin action, different diseases or a drug and/or 
chemical induction of the disease (5). Previously, the diagnosis of diabetes mellitus was 
based on fasting plasma glucose or an oral glucose tolerance test; however, in 2010, 
the American Diabetes Association included the assessment of glycated hemoglobin 
(HbA1c) into the criteria used to diagnose an individual with diabetes mellitus (5). Table 
1.1 summarizes the specific criteria used to diagnose diabetes mellitus.  
 
Table 1.1.  American Diabetes Association: Criteria for the diagnosis of diabetes 
HbA1c 
> 6.5% (Using a NGSP certified method and standardized 
to the DCCT  reference assay) 
Fasting Plasma Glucose > 126 mg/dL (No caloric intake for > 8 hours) 
2-hour Plasma Glucose 
> 126 mg/dL during an OGT test (Glucose load = 75 g 
anhydrous glucose in dissolved water) 
Random Plasma Glucose >  200 mg/dL in patients with symptoms of hyperglycemia 
Note: This table is from the American Diabetes Association (5). NGSP = National Glycohemoglobin 
Standardization Program; DCCT = Diabetes Control and Complications Trial; and OGT = Oral Glucose 
Tolerance  
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1.1.1 Type 1 Diabetes Mellitus 
 
Type 1 diabetes mellitus makes up about 5-10% of all cases and is characterized by 
the lack of insulin production (136). Previously known as juvenile diabetes, insulin-
dependent diabetes or type 1 diabetes mellitus is caused by pancreatic β-cell 
autoimmune destruction and subsequently, results in the inability for insulin production 
causing an insulin deficiency. This depletion in insulin levels results in the inability for 
the body to maintain glucose homeostasis, producing the hyperglycemic environment 
that is associated with diabetes mellitus. The rate of β-cell destruction is variable, with 
the onset occurring quickly in infants and children, to slowly in adults (12). Some forms 
of type 1 diabetes mellitus have no origination and are inherited, with these particular 
patients having insulinopenia and an increased susceptibility to ketoacidosis (12).  
 
Type 1 diabetes is known to affect a multitude of organs and systems, including 
eyes, liver, kidney, nervous system, skeletal muscle, and the heart (45). The main 
treatment for type 1 diabetes mellitus is glucose monitoring and insulin therapy, which 
will aid in the utilization of glucose. Although type 1 diabetic patients are not normally 
obese, diet and exercise allow the body to accept the insulin therapy more efficiently 
and consequently, is recommended. Other potential treatments include cell-based 
therapeutics that target immune cells in attempt to prevent against, or reverse, type 1 
diabetes mellitus (14). 
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1.1.2 Type 2 Diabetes Mellitus 
 
The more prevalent form of diabetes mellitus is classified as type 2, making 
approximately 90-95% of cases. Also known as non-insulin dependent diabetes, Type 2 
diabetes mellitus is characterized by insulin resistance and a β-cell secretory defect, 
also resulting in a hyperglycemic environment (136). Patients with type 2 diabetes 
mellitus are often obese; however, it is possible to be non-obese with this disease. 
These particular patients may have an increased body fat percentage, distributed 
mainly in the abdominal region (12). In contrast to type 1 diabetes mellitus, ketoacidosis 
is not usually present. Type 2 diabetes mellitus is more common in African, Native, and 
Asian Americans, as well as Latinos and the aged population (4). 
 
Patients with type 2 diabetes mellitus frequently go undiagnosed because of the 
slow disruption of the glucose homeostasis. These patients may have normal insulin 
levels; however, when compared to the elevated levels of blood glucose, the insulin 
levels are not high enough to compensate for the elevated blood glucose resulting in 
insulin secretion deficiency. At the beginning stages of type 2 diabetes mellitus, patients 
exhibit dyslipidemia and a lipoprotein pattern including increased triglyceride levels, low 
high density lipoprotein cholesterol values and small, dense low density lipoprotein 
particles (141). Dyslipidemia is a critical risk factor to target in attempt to prevent 
cardiovascular disease in patients with type 2 diabetes.   
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The main treatment of type 2 diabetes is diet and exercise to reduce the body 
weight in obese patients and to improve glycemic control (141, 158). By lowering body 
weight, blood glucose levels decrease; and therefore, the amount of insulin the 
pancreas secretes would be sufficient to maintain glucose homeostasis. Insulin therapy 
or medications that increase insulin sensitivity and/or decreased glucose production can 
also serve as treatment for type 2 diabetes mellitus (120).  
 
1.1.3 Significance 
 
Patients with diabetes mellitus are at an increased risk for cardiovascular 
complications, which are the leading cause of morbidity and mortality in patients with 
diabetes mellitus (66). In 2011, 8.3% of the population in the United States was 
diagnosed with diabetes mellitus. Every year, there are 1.9 million new cases diagnosed 
in individuals 20 years old or older (4, 34). By the year 2030, the incidence of diabetes 
mellitus is expected to reach 366 million (161). This vastly growing disease is quickly 
becoming an epidemic; therefore, the evaluation and identification of the mechanisms 
underlying the deleterious effects of diabetes mellitus can advance the biomedical field, 
from which therapeutic strategies can be developed and implemented. 
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1.2 Diabetic Cardiomyopathy 
 
In 1999, Grundy et al. (70) suggested that the most common complication of 
diabetes is cardiovascular disease. In the presence of hypertension and ischemic heart 
disease, patients with diabetes mellitus have an increased risk to develop heart failure. 
This development of heart failure can also occur in asymptomatic patients, without the 
presence of the hypertension or heart disease, which is termed diabetic cardiomyopathy 
(8, 21, 58, 122, 131). Characterized by cardiac contractile abnormalities and 
independent of vascular pathogenesis, diabetic cardiomyopathy was first described by 
Rubler et al. in 1972 (131) and has been associated with mitochondrial dysfunction (51, 
70, 122, 136, 147). Studies have also reported direct mitochondrial dysfunction 
associated with cardiac contractile dysfunction (62, 98) due to the decrease in ATP 
production (143). 
 
1.2.1 Cardiac contractile dysfunction 
 
The deleterious effects to the heart caused by the hyperglycemic environment 
associated with diabetes mellitus ultimately results in heart failure. Studies have 
reported increased heart failure rates in individuals with diabetes mellitus, even after 
correcting for covariables, such as age, hypertension, and coronary artery disease (11, 
19, 109). Human studies have indicated increased left ventricular mass and systolic 
dysfunction (51, 65, 144), which may contribute to the diabetic-associated decreased 
cardiac function (21). Experimental data collected from animal models indicate 
7 
 
contractile dysfunction presence as early as one week post diabetic induction (134). 
Literature has also suggested that diastolic dysfunction precedes systolic dysfunction in 
diabetic cardiomyopathy (18, 60, 100). In 2006, Galderisi stated that diabetic patients 
often develop abnormal left ventricular relaxation while the systolic function is still 
normal (64).  
 
Previously, cardiac catheterization was used to assess left ventricular diastolic 
function from which the rates of relaxation, filling and left ventricular wall stiffness was 
measured (105). More recently, non-invasive conventional echocardiography and tissue 
Doppler techniques have been used to identify and quantify diastolic dysfunction (57, 
146, 171). In normotensive diabetic patients, left ventricular dysfunction was observed 
by increased pre-ejection period and a shorter left ventricular ejection time using 
conventional echocardiography (6). Impaired left ventricular relaxation and restrictive 
filling patterns have been identified using Doppler echocardiography in diabetic patients 
(64, 111). Carugo et al. observed increased left ventricular wall thickness and mass, as 
well as a reduced E/A ratio (mitral peak velocity of early (E) and late (A) ventricular 
filling) in normotensive diabetic patients (33). Dabkowski et al. reported decreased 
cardiac function as determined by decreased rates of contraction, relaxation and 
developed pressure in Langendorff – perfused diabetic mouse hearts (48). Studies 
examining diabetic rats have shown decreased cardiac contractile performance in 
perfused, working hearts (87, 151), including decreased systolic function as measured 
by decreased speed and prolongation of cardiac contraction (59, 118). Regan et al. 
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demonstrated decreased ventricular compliance with no change is systolic function in 
diabetic dogs (121).  
 
In the diabetic heart, increases in the polyol and hexosamine pathway flux, 
advance glycation end products, and superoxide production have been reported to 
contribute to the contractile dysfunction and are suggested to be induced by the 
hyperglycemic environment (26). Along with hyperglycemia, the reduced insulin action 
and hyperlipidemia has resulted in an increase in both oxidative stress and lipotoxicity, 
as well as an alteration in calcium homeostasis (136).  
 
1.2.2 Cardiac metabolism 
 
Diabetes mellitus influences cardiac metabolism due to an altered substrate 
supply and decreased insulin action (129). Normally, 70% of the ATP production in the 
heart is derived from fatty acid oxidation compared to 30% of the energy derived from 
glucose and lactate (8). In type 1 diabetic patients, glucose uptake in the heart is 
normal, suggesting that the limiting factor is insulin (8). In type 2 diabetics, myocardial 
GLUT4 is responsible for the translocation of glucose into the tissue in order for the 
heart to derive energy through glucose oxidation. During the shift of substrate utilization, 
GLUT4 content and translocation activity is decreased, reducing the rates of glucose 
oxidation (164). Along with a decrease in glucose transport into the tissue, glucose 
supply has also been reported to be decreased in isolated diabetic cardiomyocytes (40), 
as well as in diabetic patients (112).  
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Hyperglycemia causes increased circulating free fatty acids and triglycerides, 
due to enhanced lipolysis and increased lipoprotein synthesis. Fatty acid transport 
across the plasma membrane does not require any hormone, such as insulin; therefore, 
intracellular fatty acids increase during diabetes mellitus, causing fatty acid oxidation, 
which becomes the heart’s exclusive energy source (8). As diabetes develops, the 
increased FA substrates activate peroxisome proliferator-activated receptor alpha-
mediated signaling, leading to the transcriptional induction of enzymes involved in beta 
oxidation (22). Peroxisome proliferator-activated receptor beta and AMP-activated 
protein kinase are also activated by diabetes mellitus, which promotes fatty acid 
utilization (8, 106) and turns on ATP generating processes, such as fatty acid oxidation 
and glycolysis (75, 81).  
 
Fatty acid oxidation is known to inhibit glycolysis and glucose oxidation. Along 
with these inhibitions and decrease glucose uptake, calcium homeostasis is disrupted, 
contributing to diabetic cardiomyopathy. The calcium homeostasis can also be altered 
by decreased expression of ion transporters or the Na+/Ca+ exchanger, which has been 
shown to take place during type 1 (76, 91) and type 2 diabetes (17) in animal models.  
 
1.2.3 Oxidative stress 
 
Oxidative stress is reflected by the body’s ability to balance between the 
manifestation and removal of reactive oxygen species (ROS). The hyperglycemic 
environment associated with diabetes mellitus, leads to an increase in ROS. Examples 
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of ROS include superoxide, hydrogen peroxide and hydroxyl radicals. Research 
previously published in a streptozotocin (STZ) type 1 diabetic mouse model suggested 
an increased in superoxide production (48). The body defends against the increase in 
ROS through an antioxidant defense system, which contains antioxidant enzymes that 
either inhibit ROS from being formed or scavenges ROS in attempt to maintain 
homeostasis. The antioxidant levels in the heart are lower in the presence of 
hyperglycemia, rendering the heart more susceptible to ROS damage (129). 
 
Literature has suggested that the polyol and hexosamine pathway flux, advance 
glycation end products, and activation of protein kinase C (26) are reported to be 
increased in the diabetic heart due to an increase in ROS production. Because much of 
the damage during diabetes mellitus is caused by increased ROS levels, strategies to 
decrease ROS and subsequent oxidative damage are suggested to have therapeutic 
potential (69). One study reported that different antioxidants administered to Goto-
Kakizaki rats, a type 2 diabetic rodent model, did not reverse the diabetic phenotype 
(114). In contrast, mitochondrial phospholipid hydroperoxide glutathione peroxidase 
overexpression has been shown to improve cardiac and mitochondrial function during a 
type 1 diabetic insult in mouse hearts (15). Taken together, studies have identified an 
increase in ROS production during diabetes mellitus, and as a result, alleviating the 
increased oxidative environment could serve as a potential therapeutic treatment for 
diabetes mellitus. 
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1.3 Mouse models of diabetic cardiomyopathy 
 
The mechanisms underlying human diabetic cardiomyopathy are still only partly 
understood. In order to understand diabetic cardiomyopathy more completely, both type 
1 and type 2 rodent models have been used. Even though both type 1 and type 2 
models show increased fatty acid utilization, decreased glucose utilization, and 
mitochondrial dysfunction (29), differences also exist between the two phenotypes. For 
example, increased ROS production in the hearts of type 2 diabetic models have been 
determined (28, 77), as well as fatty acid-mediated mitochondrial uncoupling induced by 
an increase in fatty acids (24, 28). Regardless of the overall similarities and differences 
between the groups, each model has helped to advance our understanding of the 
progression of diabetic cardiomyopathy. 
 
 Much of the research conducted in this area has employed mouse models, due 
to their inability to develop atherosclerosis (unless modified to do so). Our laboratory 
utilizes the type 1 diabetic STZ mouse model. STZ is a glucosamine-nitrosourea 
antibiotic that is structurally similar to glucose and is taken into pancreatic β-cells by the 
GLUT2 receptor. Through an ROS-mediated mechanism, STZ damages the pancreatic 
β-cell from which insulin cannot then be produced (145). Studies use both high dose 
and low dose STZ to render models type 1 diabetic. Our laboratory follows the protocol 
of the Animal Models of Diabetic Complications Consortium using multiple low-dose (50 
mg/kg body weight STZ dissolved in sodium citrate buffer) STZ injected intraperitoneally 
over five consecutive days. This model was chosen because it is most widely used and 
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does not induce deleterious effects associated with diabetes mellitus (165). Using this 
method, cardiac dysfunction has been observed by decreased rates of relaxation, 
contraction, developed pressure and systolic pressure (48, 90, 155) compared to 
controls. The increased levels of ROS and superoxide production affect the antioxidant 
capacity in the mitochondria, rendering mitochondria dysfunctional in the STZ model 
(48, 67, 140). Studies have identified an increase in fatty acid oxidation, along with lipid 
storage, while glucose oxidation is decreased in the STZ model (37, 61, 84). Calcium 
handling is also decreased in the STZ model; consequently impacting cardiac function 
(42, 62, 76). 
 
Alloxan is another chemical used to induce type 1 diabetes mellitus. Alloxan 
produces superoxide radials that eventually form ROS, which disrupts pancreatic β-cells 
and subsequently prevents insulin production (145). One study using alloxan-induced 
type 1 diabetic mice reported insulin secretory impairment in response to glucose (7). 
Turko et al. (149) found a common nitrating species that may underlie the nitration 
involved in mitochondria dysfunction in alloxan-susceptible mice. Aasum et al. also 
observed decreased systolic and diastolic function (1). 
 
Other type 1 diabetic models include the OVE26 mouse, the Akita mouse, the 
non-obese diabetic (NOD) mouse, and the BioBreeding (BB) rat. The OVE26 mouse 
was developed in 1989 by Epstein et al. (56) and was reported to have decreased 
cardiac contractility and mitochondrial function, along with increased oxidative stress 
(137, 138, 167). The Akita mouse, discovered in 1997 by Dr. Akio Koizumi (168), was 
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reported to have increased mitochondrial content, even though overall mitochondrial 
function was decreased (30, 31). First reported in 1980 (102) NOD mice have a 
susceptibility to spontaneously develop type 1 diabetes mellitus (93). This model 
appears to be used more for immunological responses on the development of diabetes 
(55, 95). The BB rat is a model of human type 1 diabetes mellitus, from which two 
inbred lines have been created: one that is prone to diabetes and the other is diabetic 
resistant (160). The diabetic prone BB develops type 1 diabetes mellitus within 2 to 3 
months. The diabetic resistant needs to be virally  infected in order to develop diabetes 
(88). Interestingly, Rodrigues and McNeill observed cardiac dysfunction in perfused 
hearts from diabetic-prone BB rats, similar to the dysfunction observed in STZ rats and 
the human population (126). 
 
Rodent models of type 2 diabetes include the ob/ob mouse, the db/db mouse, 
and the Zucker diabetic fatty rat. Both the ob/ob and db/db mouse were derived by 
targeting the same mechanism. The ob/ob mouse resulted from a mutation in the leptin 
gene (172), where as the db/db is a consequence of an impaired leptin receptor (44). 
The ob/ob mouse develops type 2 diabetes by 15 weeks, even though they display 
higher insulin levels and lower glucose tolerance by only 5 weeks (27). Compared to the 
ob/ob, the db/db mouse is has a normal glucose tolerance at 4 weeks, but develops 
type 2 diabetes at 8 weeks (27). Due to the earlier manifestation of type 2 diabetes, the 
db/db mouse has greater contractile abnormalities (170). In both models, fatty acid 
oxidation rates and oxidative stress levels are increased, while glucose oxidation rates 
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are decreased (17, 24, 27, 29, 99, 103, 170). Mitochondrial dysfunction is also evident 
in both models (23, 24). 
 
The Zucker diabetic fatty rat, like the db/db, contains a mutation in the leptin 
receptor, which is the cause of type 2 diabetes mellitus. Hyperglycemia develops 
around 6 weeks of age; however, the high blood glucose levels are not stable until 10 -
12 weeks, when the insulin levels start to fall (29). The Zucker diabetic fatty rat has not 
been studied as extensively as the mouse type 2 diabetic models. Even though cardiac 
size is increased in this model (29), cardiac function is decreased (117, 169). The 
decreased contractile function could be contributed to the increase in fatty acid 
availability, which would also increase fatty acid oxidation (169). Carbohydrate oxidation 
is also seen to decrease during the type 2 diabetic state (38).  
 
 
1.4 Mitochondrial Subpopulations 
 
Two distinct mitochondrial subpopulations are present in striated muscle: 
subsarcolemmal (SSM) and interfibrillar mitochondria (IFM) (48, 116, 124) (Figure 1.1). 
Each population is spatially, morphologically and functionally distinct. The SSM are 
located just beneath the sarcolemma and produce primarily operate to actively transport 
electrolytes and metabolites across the sarcolemma. They are larger in size and contain 
lamelliform cristae (124). The IFM are situated between the myofibrils, are smaller, 
more compact in size. Their cristae are lamelliform and tubular in shape, allowing for a 
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higher concentration of protons, and subsequently, higher ATP synthase activity (124). 
Compared to the SSM, the IFM have higher membrane potential and state 3 respiration 
rates, as well as increased ATP production (157, 163). Their main function is suggested 
to be to generate ATP for muscle contraction (48). 
 
 
 
Figure 1.1. Mitochondrial subpopulations. 
Electron micrograph of the placement of 
subsarcolemmal mitochondria (SSM)  and 
interfibrillar mitochondria (IFM) in the heart 
muscle (in situ) (79). 
 
 
Literature has suggested that the two mitochondrial pools respond differently to 
pathological insults, such as ischemia/reperfusion, aging, heart failure and diabetes (39, 
47, 48, 80, 97, 123, 130). Chen et al. reported decreased mitochondrial respiration 
through cytochrome oxidase, as well as increased hydrogen peroxide production from 
electron transport chain (ETC) complexes I and III in both SSM and IFM after an 
ischemic insult (39). Although, Lesnefsky et al. also reported an ischemia-mediated 
mitochondrial respiration decrease through cytochrome oxidase, the SSM were the only 
subpopulation affected (97). Aging also greatly impacts mitochondrial function. In 2002, 
Hoppel et al. (80) reported decreased oxidative phosphorylation through ETC complex 
III and IV, specifically in the IFM, of aged rats compared to control (80). Rosca et al. 
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reported increased ETC complex I and complex III in the SSM, with no change in ETC 
complex IV in canine coronary heart failure model as measured by Native PAGE (130). 
Type 1 and type 2 diabetes mellitus affect the mitochondrial subpopulations. 
Interestingly, type 1 diabetes mellitus has been shown to affect the IFM (48), whereas 
type 2 diabetes affects the SSM (47, 123). Although the presence of hyperglycemia 
leads to the phenotype of both type 1 and type 2 diabetes mellitus, it is unclear as to 
why mitochondrial subpopulations are differentially affected. It has been suggested that 
the spatial arrangement and environment of the distinct subpopulations allow for the 
mitochondria to be impacted differently in response to pathological insults. For example, 
type 2 diabetes mellitus is characterized by high levels of triglyceride accumulation and 
lipid deposition (110), which could be the potential mechanism contributing to the 
dysfunctional SSM, when compared to IFM during a type 2 diabetic insult, because of 
the sub-sarcolemmal location of the SSM (110). 
 
 
1.5 Mitochondrial dysfunction in the diabetic heart 
 
Hyperglycemia is a recognized complication of both type 1 and type 2 diabetes 
(132) and in combination with oxidative stress and subsequent increased production of 
ROS, deleterious effects cause the heart and the organelles that reside within, such as 
mitochondria, to become dysfunctional (125, 128, 138). Mitochondria are the main 
source of ROS in cells and the effects of ROS damage have been linked to different 
pathologies, such as ischemia/reperfusion injury, atherosclerosis, and diabetes mellitus 
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(52, 115). Literature suggests that the increase in ROS production is the unifying 
mechanism underlying mitochondrial dysfunction during both type 1 and type 2 diabetes 
mellitus (26).   
 
1.5.1 Mitochondrial oxidative stress 
 
Mitochondria are more vulnerable to oxidative stress than other organelle 
because the inner mitochondrial membrane (156) is the primary source of ROS 
production, specifically at ETC complex I and complex III (115). ROS are suggested to 
induce lipid modifications, DNA damage and protein damage (153). Along with the 
elevated levels of free fatty acids observed during diabetes mellitus, lipid peroxidation 
and membrane disruption are more likely to occur (53, 68) given the increase in ROS 
production. Our laboratory reported increased damage to proteins and lipids, as 
determined by nitrotyrosine content and lipid peroxidation in type 1 diabetic IFM, 
respectively (48). Interestingly, animal models manipulated to overexpress players 
involved in the antioxidant defense system, such as manganese superoxide dismutase 
and mitochondrial phospholipid hydroperoxide glutathione peroxidase, have provided 
protection against mitochondrial dysfunction associated with diabetes mellitus (15, 137). 
 
1.5.2 Calcium homeostasis 
 
The uptake of calcium into mitochondria regulates mitochondrial metabolism (54) 
and acts to stimulate oxidative phosphorylation (13, 49, 74, 104). When needed, the 
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calcium influx is increased enhancing ATP production in order to meet the ATP demand 
needed to increase contractile force. In the presence of a pathological stimulus, calcium 
entering mitochondria increases ROS by increasing oxidative phosphorylation. 
Alteration in calcium homeostasis can also activate the opening of the mitochondrial 
permeability transition pore (mPTP) and subsequently trigger apoptosis (25). One study 
using type 1 diabetic rats, reported decreased calcium uptake, along with increased 
mPTP opening (113). In agreement, our laboratory observed increased mPTP opening 
in the IFM of type 1 diabetic mouse hearts (162). In conjunction with the increased 
mPTP opening, an observed increase in cytochrome c release suggested damage to 
the anchoring phospholipid environment, also an effect of increased ROS generation. 
 
1.5.3 Lipotoxicity 
 
Obesity associated with diabetes mellitus is linked to excess lipid deposition in 
multiple tissues, including the heart (159). The tissues can store some of the lipid 
deposition as triglycerides; however, the excess lipid deposition can cause lipotoxic 
effects, affecting multiple processes. For example, the excess lipids are forced through 
the oxidative machinery, causing mitochondrial dysfunction (166) and cardiac 
dysfunction (78).  
 
In regards to mitochondrial dysfunction, augmented lipid accumulation increases 
mitochondrial fatty acid oxidation, which in turn alters different pathways that all lead to 
cardiac contractile dysfunction. Literature has reported reduced ATP generation in the 
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presence of increased fatty acid oxidation indicative of mitochondrial uncoupling (23). 
Further, an increase in fatty acid oxidation is associated with increased ROS production 
(154), which then oxidizes lipids contributing to mitochondrial and cardiac dysfunction. 
 
1.5.4 Mitochondrial dysfunction in the type 1 diabetic heart 
 
Even though mitochondrial dysfunction in the type 1 diabetic heart has been 
identified, the mechanisms underlying the dysfunction are still being evaluated. 
Mitochondrial respiration has been reported to be decreased during type 1 diabetes 
mellitus using different substrates (48, 96, 152). Proteomic alterations have been 
identified in the type 1 diabetic heart, with IFM being affected to a greater extent than 
SSM (16). We and others have shown a decrease in ETC function during a type 1 
diabetic insult, specifically in IFM (48, 96). ROS production has been shown to be 
increased in type 1 OVE26 mice (142), as well as an increase in apoptotic susceptibility, 
specifically in the IFM (162), all of which contributing to the observed mitochondrial 
dysfunction. 
 
1.5.5 Mitochondrial dysfunction in the type 2 diabetic heart 
 
Many of the same characteristics of mitochondrial dysfunction reported from type 
1 animal models are also reported from type 2 animal models; however, the diabetic 
phenotypes between the two types include important differences. It is interesting to 
point out that much of the mitochondrial dysfunction occurs in the SSM to a greater 
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extent than the IFM during a type 2 diabetic insult, which is in contrast to type 1 
diabetes mellitus. Obesity is associated with type 2 diabetes mellitus; therefore, 
increases in lipid deposition cause much of the dysfunction during type 2 diabetes. 
Mitochondrial respiration was reported to be decreased in the presence of both 
glutamate and palmitoylcarnitine in a type 2 diabetic animal model, specifically in the 
SSM (47). This finding is supported by total mitochondria isolated from human atrial 
tissues, from which mitochondrial respiration in the presence of palmitoylcarnitine is 
also decreased (9). The increased lipid deposition leads to increased lipid peroxidation 
and subsequent ROS production. Further contributing to mitochondrial dysfunction 
associated with type 2 diabetes mellitus is the proteomic alterations observed in the 
diabetic SSM, of which many are involved in mitochondrial processes that are housed in 
the IMM (156). 
 
 
1.6 Inner Mitochondrial Membrane 
 
A critical component of the mitochondrion is the IMM (156) (Figure 1.2), which is 
composed of a specific lipid environment that houses many proteins required for proper 
mitochondrial function. This membrane is the primary source of ROS generation, 
making the IMM susceptible to oxidative damage. Subsequently, the integrity of the lipid 
environment of the IMM is altered due to the increase in ROS and oxidative damage, 
further enhancing mitochondrial dysfunction (159). The increased ROS target the lipids 
of the IMM due to their highly unsaturated structure, causing enhanced lipid 
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peroxidation (85) leading to disassociation of lipids and critical proteins that reside in the 
IMM, such as the  ETC complexes (2). During type 1 diabetes mellitus, ETC proteins 
are decreased (16) along with their associated activities (48).  
 
 
Figure 1.2. Schematic of the inner mitochondrial membrane. PE = Phosphatidyl-
ethanolamine; PI = Phosphatidylinositol; LPE = Lyso-phosphatidylethanolamine; VDAC 
= voltage dependent anion channel; and ANT = adenine nucleotide transporter. 
 
1.6.1 Inner mitochondrial membrane machinery 
 
The IMM houses many proteins required for proper mitochondrial function, 
including the machinery that produces ATP, ETC complexes, and protein import 
machinery (Figure 1.2). Proteomic data has revealed that the IMM contains the highest 
percentage of proteins affected by a diabetic insult (16). During a type 1 insult, IFM 
proteins are affected to a greater extent compared to SSM proteins. Many of these 
altered proteins are also affected during a type 2 diabetic insult, with the SSM being 
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affected to a greater extent (47). An example of this phenomenon would be glucose 
regulated protein 75 (Grp75), which is a key constituent in the protein import process. 
 
Also housed in the IMM are the constituents involved in mitochondrial-mediated 
apoptosis, such as the cytochrome c anchoring mechanism and adenine nucleotide 
transporter, which forms a pore with voltage dependent anion channel to release 
cytochrome c. The release of cytochrome c occurs when the anchoring lipids are 
damaged during a pathological insult, in this case, diabetes mellitus. The phospholipid 
environment is critical for the associated proteins to function properly. The impaired 
mitochondrial function reported during a diabetic insult can be partially explained by 
examining the IMM phospholipid environment, which contains a unique phospholipid, 
cardiolipin. 
 
1.6.2 Cardiolipin and the Biosynthesis Pathway 
 
Cardiolipin is thought to play a key role in mitochondrial structure and 
bioenergetics (2). Most abundant in the mammalian heart, cardiolipin is primarily located 
in the IMM (133); however, literature suggests the presence of cardiolipin in the outer 
mitochondrial membrane (50, 83). Cardiolipin is a unique phospholipid with a dimeric 
structure containing three glycerol backbones and four fatty acyl side chains (133) 
(Figure 1.3).  
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Figure 1.3. Structure of tetralinoleoyl cardiolipin. Adapted from (94) 
  
The biosynthetic pathway of cardiolipin starts in the outer mitochondrial 
membrane where phosphatidic acid is converted into cytidine diphosphate 
diacylglycerol (CDP-DAG) by cytidine diphosphate diacylglycerol synthase (CDS). 
Phosphatidylglycerol synthase (PGS) then converts CDP-DAG to phosphatidyl-glycerol 
phosphate (PG-P), where the phosphate is removed by phosphatidyl-glycerol 
phosphatase (PGP), resulting in the formation of phosphatidylglycerol (PG). Cardiolipin 
synthase (CRLS) catalyzes the condensation of CDP-DAG with PG, resulting in a 
nascent form of cardiolipin (41, 101). Because the substrates used to make cardiolipin 
do not contain the precise fatty acyl side chains for the specific tissue, a remodeling 
process takes place converting the nascent form of cardiolipin to the mature form 
containing specific fatty acyl side chains (41) (Figure 1.4).  
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Figure 1.4. Cardiolipin biosynthetic pathway. Schematic illustrating cardiolipin 
synthesis. PLA2= phospholipase A2; MLCL= monolyso-cardiolipin; TAZ= Tafazzin. Refer 
to text for other abbreviations. 
 
Depending on the tissue and environment, the side chains of cardiolipin are 
composed of different fatty acids. Linoleic acid is the most abundant fatty acid side 
chain found to compose the mature form of cardiolipin in cardiac mitochondria, 
constituting about 80% of all cardiolipin (3, 133) (Figure 1.3). Each side chain of a tetra-
linoleoyl cardiolipin contains eighteen carbons with two double bonds, with the double 
bonds serving as targets for ROS and oxidative damage (82, 85). The side chains of 
cardiolipin create a conical shaped lipid (82), allowing it to interact with IMM proteins 
and facilitate proper mitochondrial function.  
 
Cardiolipin has been suggested to be involved in protein import (82, 148), 
membrane stability (133), and cytochrome c attachment (85, 119). Other proteins that 
rely on cardiolipin for proper function and activity are carriers of the IMM, such as 
adenine nucleotide translocator (20), and  carnitine (86), pyruvate and phosphate 
carriers (89, 107). Literature suggests an interaction between cardiolipin and the ETC 
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complexes involved in oxidative phosphorylation (133), such as ETC complex I, III, IV, 
and ATP synthase (63, 135).  
 
This important lipid has been shown to play a critical role in the organization of 
mammalian mitochondrial ATP synthase. It has been suggested that the IMM-bound F0 
complex of ATP synthase contains high affinity binding sites for cardiolipin (2); however, 
these specific binding sites are unknown. Cardiolipin is also known to trap protons 
within its polar head group, serving as a proton reservoir to maintain IMM potential and 
to contribute to ATP synthesis (72). Shotgun lipidomics have revealed decreased tetra-
linoleic cardiolipin content in diabetic mouse hearts and the authors have suggested a 
possible mechanistic reliance on the interaction between IMM protein activity and 
cardiolipin (73). 
 
 
1.7 Protein Import 
 
There are over 1500 proteins in the human mitochondria, of which only 13 are 
transcribed and translated in the organelle (10, 32). The remaining 99% of the nuclear 
encoded mitochondrial proteins need to be imported into the mitochondria through a 
complex process. Proteomic analyses indicate a decreased abundance of nuclear 
encoded proteins during a diabetic insult, which included proteins essential for proper 
mitochondrial import processes (46, 150).  
 
26 
 
 
 
Figure 1.5.  Mitochondrial import of matrix-targeted proteins. Schematic 
illustrating the protein import process (92). 
 
Protein import is mutli-step, complex pathway from which nuclear-encoded 
proteins enter the mitochondria (Figure 1.5). The constituents involved in this process, 
outer membrane translocases (Tom), inner membrane translocases (Tim), and the 
presquence translocase-associated motor (PAM), create a supercomplex that facilitates 
the movement of proteins into the matrix (36). The protein import process begins 
outside of the mitochondrion, where N-terminal pre-proteins are recognized by outer 
mitochondrial membrane receptors Tom20 and Tom22. The pre-proteins then pass 
through Tom40 and enter the inner mitochondrial space. Proteins that are targeted for 
the matrix will then bind to the main IMM protein import pore, Tim23, with the help of 
Tim21 and Tim50. Tim50 recruits the PAM complex, which pulls the pre-protein into the 
matrix. The key constituent of the PAM complex, Grp75, also known as mortalin or 
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mitochondrial heat shock protein 70 (mthsp70), binds to Tim44 on the matrix side and 
through an energy-driven mechanism, diassociates from Tim44, pulling the pre-protein 
completely into the matrix (156). Matrix-processing peptidase (MPP) cleaves the 
targeting sequence from the pre-protein. The protein is then properly hsp60 and hsp10, 
resulting in a mature protein in the mitochondrial matrix (35, 71, 92, 108, 139). 
Depending on the N-terminal presequence, the protein can be targeted for either the 
matrix, IMM, outer mitochonrial membrane or inter mitochondrial membrane space. 
 
Mitochondrial protein import has been shown to be decreased in a type 1 diabetic 
setting, specifically in the IFM (15). By using a novel mitochondrial protein import assay, 
protein import rates into mitochodria can be measured (15).  Figure 1.6A is a vector 
map that illustrates the MitoGFP plasmid that is grown in a cell-free bacterial protein 
lysate system. When the lysate is incubated with mitochondria in the presence of 
substrates necessary for the import process to occur, protein import of MitoGFP1 is 
initiated. Following a 10 minute incubation period, import is stopped and after 
processing the mitochondria, a Western blot is performed to determine the amount of 
MitoGFP1 that has been imported into the mitochondria. Figure 1.6B illustrates the 
resulting Western blot probed for MitoGFP1, with lane 1 representing mitochondria 
without the lysate, lane 2 depicting the lysate without mitochondria, whereas lane 3 
demonstrates the presence of MitoGFP1 when mitochondria and the lysate are 
incubated together. The top band, measured at 31 kDa, respresents the unprocessed 
mitoGFP1 that has not yet been imported into the mitochondria. The bottom band, 
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measured at 28 kDa, respresents the processed mitoGFP1that has been imported into 
the mitochondria. 
 
 
A. B. 
 
 
 
Figure 1.6. MitoGFP1 construct and protein import. (A.) pMITOGFP1 plasmid.  (B.)  
Western blot of MitoGFP1 protein import into isolated cardiac mitochondria probed for 
MitoGFP1 in samples containing mitochondria only (lane 1), MitoGFP1 protein lysate 
(lane 2), or combined mitochondria and lysate (lane 3).   Upper 31 kD band represents 
the full length precursor MitoGFP1 un- processed; lower 27 kD band represents mature 
cleaved MitoGFP1 protein residing within the mitochondrial matrix. 
 
Baseler et al. previously reported protein import deficiency in type 1 diabetic 
mice, specifically in the IFM (16). The deficiency was attributed to decreased Grp75 
protein content in the diabetic IFM compared to control, with no observed differences in 
Mito       Lysate       Mito +
Lysate
31 kD
1             2              3  
27 kD
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the SSM regarding protein import or Grp75 protein content (16). To date, protein import 
has not been reported in a type 2 diabetic mouse model, nor in a diabetic human model. 
 
1.8 Summary 
 
In the United States, heart failure is the leading cause of mortality in patients with 
DM (66). In 2010, 11.3% of the U.S. population age 20 and older suffered from diabetes 
(43) and each year, approximately 15,000 more people over the age of 20 are 
diagnosed with type 1 diabetes (127). Cardiovascular complications that arise from 
diabetes mellitus, such as diabetic cardiomyopathy, are becoming a more prevalent tool 
used for the diagnosis of heart failure; however, possible mechanisms involving 
mitochondrial dysfunction associated with diabetic cardiomyopathy need to be further 
examined to advance our understanding of the disease and its development. The goal 
of this dissertation was to evaluate the impact of type 1 diabetes mellitus on the IMM 
phospholipid environment, specifically cardiolipin, and the processes that are housed 
within. Further, the mitochondrial dysfunction in the type 2 diabetic human heart was 
examined with the intention of discovering potential targets for future therapeutic 
strategies. 
 
  
30 
 
1.9 References 
 
1. Aasum E, Belke DD, Severson DL, Riemersma RA, Cooper M, Andreassen 
M, and Larsen TS. Cardiac function and metabolism in Type 2 diabetic mice after 
treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ 
Physiol 283: H949-957, 2002. 
2. Acehan D, Malhotra A, Xu Y, Ren M, Stokes DL, and Schlame M. Cardiolipin 
affects the supramolecular organization of ATP synthase in mitochondria. Biophys J 
100: 2184-2192, 2011. 
3. Acehan D, Vaz F, Houtkooper RH, James J, Moore V, Tokunaga C, Kulik W, 
Wansapura J, Toth MJ, Strauss A, and Khuchua Z. Cardiac and skeletal muscle 
defects in a mouse model of human Barth syndrome. J Biol Chem 286: 899-908, 2011. 
4. ADA. American Diabetes Association: Diabetes Basics, 2013. 
5. ADA. Standards of Medical Care in Diabetes -2013. Diabetes Care 36: S11-S66, 
2013. 
6. Ahmed SS, Jaferi GA, Narang RM, and Regan TJ. Preclinical abnormality of 
left ventricular function in diabetes mellitus. Am Heart J 89: 153-158, 1975. 
7. Ahren B and Sundkvist G. Long-term effects of alloxan in mice. Int J Pancreatol 
17: 197-201, 1995. 
8. An D and Rodrigues B. Role of changes in cardiac metabolism in development 
of diabetic cardiomyopathy. American Journal of Physiology - Heart and Circulatory 
Physiology 291: H1489-H1506, 2006. 
9. Anderson EJ, Kypson AP, Rodriguez E, Anderson CA, Lehr EJ, and Neufer 
PD. Substrate-Specific Derangements in Mitochondrial Metabolism and Redox Balance 
31 
 
in the Atrium of the Type 2 Diabetic Human Heart. Journal of the American College of 
Cardiology 54: 1891-1898, 2009. 
10. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, 
Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, and 
Young IG. Sequence and organization of the human mitochondrial genome. Nature 
290: 457-465, 1981. 
11. Aronow WS and Ahn C. Incidence of heart failure in 2,737 older persons with 
and without diabetes mellitus. Chest 115: 867-868, 1999. 
12. Association AD. Diagnosis and Classification of Diabetes Mellitus. Diabetes 
Care 33: S62-S69, 2010. 
13. Balaban RS. Cardiac Energy Metabolism Homeostasis: Role of Cytosolic 
Calcium. Journal of Molecular and Cellular Cardiology 34: 1259-1271, 2002. 
14. Barcala Tabarrozzi AE, Castro CN, Dewey RA, Sogayar MC, Labriola L, and 
Perone MJ. Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus. 
Clinical & Experimental Immunology 171: 135-146, 2013. 
15. Baseler WA, Dabkowski ER, Jagannathan R, Thapa D, Nichols CE, 
Shepherd DL, Croston TL, Powell M, Razunguzwa TT, Lewis SE, Schnell DM, and 
Hollander JM. Reversal of mitochondrial proteomic loss in Type 1 diabetic heart with 
overexpression of phospholipid hydroperoxide glutathione peroxidase. Am J Physiol 
Regul Integr Comp Physiol 304: R553-565, 2013. 
16. Baseler WA, Dabkowski ER, Williamson CL, Croston TL, Thapa D, Powell 
MJ, Razunguzwa TT, and Hollander JM. Proteomic alterations of distinct 
32 
 
mitochondrial subpopulations in the type 1 diabetic heart: contribution of protein import 
dysfunction. Am J Physiol Regul Integr Comp Physiol 300: R186-200, 2011. 
17. Belke DD, Larsen TS, Gibbs EM, and Severson DL. Altered metabolism 
causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol 
Endocrinol Metab 279: E1104-1113, 2000. 
18. Bell DSH. Diabetic Cardiomyopathy. Diabetes Care 26: 2949-2951, 2003. 
19. Bertoni AG, Tsai A, Kasper EK, and Brancati FL. Diabetes and idiopathic 
cardiomyopathy: a nationwide case-control study. Diabetes Care 26: 2791-2795, 2003. 
20. Beyer K and Klingenberg M. ADP/ATP carrier protein from beef heart 
mitochondria has high amounts of tightly bound cardiolipin, as revealed by 31P nuclear 
magnetic resonance. Biochemistry 24: 3821-3826, 1985. 
21. Boudina S and Abel ED. Diabetic cardiomyopathy revisited. Circulation 115: 
3213-3223, 2007. 
22. Boudina S and Abel ED. Diabetic cardiomyopathy, causes and effects. Rev 
Endocr Metab Disord 11: 31-39, 2010. 
23. Boudina S, Sena S, O'Neill BT, Tathireddy P, Young ME, and Abel ED. 
Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling 
impair myocardial energetics in obesity. Circulation 112: 2686-2695, 2005. 
24. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, 
Johnson JI, Bugger H, Zaha VG, and Abel ED. Mitochondrial energetics in the heart 
in obesity-related diabetes: direct evidence for increased uncoupled respiration and 
activation of uncoupling proteins. Diabetes 56: 2457-2466, 2007. 
33 
 
25. Brookes PS, Yoon Y, Robotham JL, Anders MW, and Sheu S-S. Calcium, 
ATP, and ROS: a mitochondrial love-hate triangle. American Journal of Physiology - 
Cell Physiology 287: C817-C833, 2004. 
26. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. 
Diabetes 54: 1615-1625, 2005. 
27. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, 
Cooksey RC, Litwin SE, and Abel ED. Reduced cardiac efficiency and altered 
substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction 
in two mouse models of insulin resistance and obesity. Endocrinology 146: 5341-5349, 
2005. 
28. Bugger H and Abel ED. Molecular mechanisms for myocardial mitochondrial 
dysfunction in the metabolic syndrome. Clin Sci (Lond) 114: 195-210, 2008. 
29. Bugger H and Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model 
Mech 2: 454-466, 2009. 
30. Bugger H, Boudina S, Hu XX, Tuinei J, Zaha VG, Theobald HA, Yun UJ, 
McQueen AP, Wayment B, Litwin SE, and Abel ED. Type 1 diabetic akita mouse 
hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain 
coupled despite increased uncoupling protein 3. Diabetes 57: 2924-2932, 2008. 
31. Bugger H, Chen D, Riehle C, Soto J, Theobald HA, Hu XX, Ganesan B, 
Weimer BC, and Abel ED. Tissue-specific remodeling of the mitochondrial proteome in 
type 1 diabetic akita mice. Diabetes 58: 1986-1997, 2009. 
34 
 
32. Calvo S, Jain M, Xie X, Sheth SA, Chang B, Goldberger OA, Spinazzola A, 
Zeviani M, Carr SA, and Mootha VK. Systematic identification of human mitochondrial 
disease genes through integrative genomics. Nat Genet 38: 576-582, 2006. 
33. Carugo S, Giannattasio C, Calchera I, Paleari F, Gorgoglione MG, Grappiolo 
A, Gamba P, Rovaris G, Failla M, and Mancia G. Progression of functional and 
structural cardiac alterations in young normotensive uncomplicated patients with type 1 
diabetes mellitus. J Hypertens 19: 1675-1680, 2001. 
34. CDC. National diabetes fact sheet: national estimates and general information on 
diabetes and prediabetes in the United States, 2011. : Atlanta, GA: U.S. Department of 
Health and Human Services, Centers for Disease Control and Prevention, 2011. 
35. Chacinska A, Lind M, Frazier AE, Dudek J, Meisinger C, Geissler A, 
Sickmann A, Meyer HE, Truscott KN, Guiard B, Pfanner N, and Rehling P. 
Mitochondrial presequence translocase: switching between TOM tethering and motor 
recruitment involves Tim21 and Tim17. Cell 120: 817-829, 2005. 
36. Chacinska A, Rehling P, Guiard B, Frazier AE, Schulze-Specking A, Pfanner 
N, Voos W, and Meisinger C. Mitochondrial translocation contact sites: separation of 
dynamic and stabilizing elements in formation of a TOM-TIM-preprotein supercomplex. 
Embo J 22: 5370-5381, 2003. 
37. Chatham JC and Forder JR. Relationship between cardiac function and 
substrate oxidation in hearts of diabetic rats. Am J Physiol 273: H52-58, 1997. 
38. Chatham JC and Seymour AM. Cardiac carbohydrate metabolism in Zucker 
diabetic fatty rats. Cardiovasc Res 55: 104-112, 2002. 
35 
 
39. Chen Q, Moghaddas S, Hoppel CL, and Lesnefsky EJ. Ischemic defects in the 
electron transport chain increase the production of reactive oxygen species from 
isolated rat heart mitochondria. Am J Physiol Cell Physiol 294: C460-466, 2008. 
40. Chen V, Ianuzzo CD, Fong BC, and Spitzer JJ. The effects of acute and 
chronic diabetes on myocardial metabolism in rats. Diabetes 33: 1078-1084, 1984. 
41. Chicco AJ and Sparagna GC. Role of cardiolipin alterations in mitochondrial 
dysfunction and disease. Am J Physiol Cell Physiol 292: C33-44, 2007. 
42. Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, Dilly KW, Guatimosim S, 
Lederer WJ, and Matlib MA. Defective intracellular Ca(2+) signaling contributes to 
cardiomyopathy in Type 1 diabetic rats. Am J Physiol Heart Circ Physiol 283: H1398-
1408, 2002. 
43. Clearinghouse NDI. National Diabetes Statistics, 2011. 
44. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity 
syndromes in mice. Diabetologia 14: 141-148, 1978. 
45. Control CfD. National Diabetes Fact Sheet. 2011. 
46. Dabkowski ER. Quantitative proteomic analysis of distinct mitochondrial 
subpopulations in diabetic myocardium. FASEB J 22, 2008. 
47. Dabkowski ER, Baseler WA, Williamson CL, Powell M, Razunguzwa TT, 
Frisbee JC, and Hollander JM. Mitochondrial dysfunction in the type 2 diabetic heart is 
associated with alterations in spatially distinct mitochondrial proteomes. Am J Physiol 
Heart Circ Physiol 299: H529-540, 2010. 
48. Dabkowski ER, Williamson CL, Bukowski VC, Chapman RS, Leonard SS, 
Peer CJ, Callery PS, and Hollander JM. Diabetic cardiomyopathy-associated 
36 
 
dysfunction in spatially distinct mitochondrial subpopulations. Am J Physiol Heart Circ 
Physiol 296: H359-369, 2009. 
49. Das AM and Harris DA. Control of mitochondrial ATP synthase in heart cells: 
inactive to active transitions caused by beating or positive inotropic agents. 
Cardiovascular Research 24: 411-417, 1990. 
50. de Kroon AIPM, Dolis D, Mayer A, Lill R, and de Kruijff B. Phospholipid 
composition of highly purified mitochondrial outer membranes of rat liver and 
Neurospora crassa. Is cardiolipin present in the mitochondrial outer membrane? 
Biochimica et Biophysica Acta (BBA) - Biomembranes 1325: 108-116, 1997. 
51. Devereux RB, Roman MJ, Paranicas M, OÂ’Grady MJ, Lee ET, Welty TK, 
Fabsitz RR, Robbins D, Rhoades ER, and Howard BV. Impact of Diabetes on 
Cardiac Structure and Function : The Strong Heart Study. Circulation 101: 2271-2276, 
2000. 
52. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 
82: 47-95, 2002. 
53. Drummen GPC, van Liebergen LCM, Op den Kamp JAF, and Post JA. C11-
BODIPY581/591, an oxidation-sensitive fluorescent lipid peroxidation probe: 
(micro)spectroscopic characterization and validation of methodology. Free Radical 
Biology and Medicine 33: 473-490, 2002. 
54. Duchen MR. Mitochondria and calcium: from cell signalling to cell death. The 
Journal of Physiology 529: 57-68, 2000. 
37 
 
55. Engkilde K, Buschard K, Hansen AK, Menne T, and Johansen JD. 
Prevention of diabetes in NOD mice by repeated exposures to a contact allergen 
inducing a sub-clinical dermatitis. PLoS One 5: e10591, 2010. 
56. Epstein PN, Overbeek PA, and Means AR. Calmodulin-induced early-onset 
diabetes in transgenic mice. Cell 58: 1067-1073, 1989. 
57. Fang ZY, Prins JB, and Marwick TH. Diabetic Cardiomyopathy: Evidence, 
Mechanisms, and Therapeutic Implications. Endocrine Reviews 25: 543-567, 2004. 
58. Fein FS. Diabetic cardiomyopathy. Diabetes Care 13: 1169-1179, 1990. 
59. Fein FS, Kornstein LB, Strobeck JE, Capasso JM, and Sonnenblick EH. 
Altered myocardial mechanics in diabetic rats. Circ Res 47: 922-933, 1980. 
60. Fein FS and Sonnenblick EH. Diabetic cardiomyopathy. Cardiovasc Drugs Ther 
8: 65-73, 1994. 
61. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, 
Gross RW, Kozak R, Lopaschuk GD, and Kelly DP. The cardiac phenotype induced 
by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 
109: 121-130, 2002. 
62. Flarsheim CE, Grupp IL, and Matlib MA. Mitochondrial dysfunction 
accompanies diastolic dysfunction in diabetic rat heart. American Journal of Physiology 
- Heart and Circulatory Physiology 271: H192-H202, 1996. 
63. Fry M and Green DE. Cardiolipin requirement for electron transfer in complex I 
and III of the mitochondrial respiratory chain. Journal of Biological Chemistry 256: 1874-
1880, 1981. 
38 
 
64. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by 
Doppler echocardiography. J Am Coll Cardiol 48: 1548-1551, 2006. 
65. Galderisi M, Anderson KM, Wilson PW, and Levy D. Echocardiographic 
evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart 
Study). Am J Cardiol 68: 85-89, 1991. 
66. Garcia MJ, McNamara PM, Gordon T, and Kannel WB. Morbidity and mortality 
in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 23: 
105-111, 1974. 
67. Ghosh S, Pulinilkunnil T, Yuen G, Kewalramani G, An D, Qi D, Abrahani A, 
and Rodrigues B. Cardiomyocyte apoptosis induced by short-term diabetes requires 
mitochondrial GSH depletion. Am J Physiol Heart Circ Physiol 289: H768-776, 2005. 
68. Green K, Brand MD, and Murphy MP. Prevention of Mitochondrial Oxidative 
Damage as a Therapeutic Strategy in Diabetes. Diabetes 53: S110-S118, 2004. 
69. Green K, Brand MD, and Murphy MP. Prevention of mitochondrial oxidative 
damage as a therapeutic strategy in diabetes. Diabetes 53 Suppl 1: S110-118, 2004. 
70. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch 
W, Smith SC, Jr., and Sowers JR. Diabetes and cardiovascular disease: a statement 
for healthcare professionals from the American Heart Association. Circulation 100: 
1134-1146, 1999. 
71. Gupta RS. Evolution of the chaperonin families (Hsp60, Hsp10 and Tcp-1) of 
proteins and the origin of eukaryotic cells. Mol Microbiol 15: 1-11, 1995. 
72. Haines TH and Dencher NA. Cardiolipin: a proton trap for oxidative 
phosphorylation. FEBS Letters 528: 35-39, 2002. 
39 
 
73. Han X, Yang J, Cheng H, Yang K, Abendschein DR, and Gross RW. Shotgun 
lipidomics identifies cardiolipin depletion in diabetic myocardium linking altered 
substrate utilization with mitochondrial dysfunction. Biochemistry 44: 16684-16694, 
2005. 
74. Hansford RG and Zorov D. Role of mitochondrial calcium transport in the 
control of substrate oxidation. Mol Cell Biochem 184: 359-369, 1998. 
75. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key 
sensor of cellular energy status. Endocrinology 144: 5179-5183, 2003. 
76. Hattori Y, Matsuda N, Kimura J, Ishitani T, Tamada A, Gando S, Kemmotsu 
O, and Kanno M. Diminished function and expression of the cardiac Na+-Ca2+ 
exchanger in diabetic rats: implication in Ca2+ overload. J Physiol 527 Pt 1: 85-94, 
2000. 
77. Herlein JA, Fink BD, O'Malley Y, and Sivitz WI. Superoxide and respiratory 
coupling in mitochondria of insulin-deficient diabetic rats. Endocrinology 150: 46-55, 
2009. 
78. Hexeberg S, Hessevik I, and Hexeberg E. Intravenous lipid infusion results in 
myocardial lipid droplet accumulation combined with reduced myocardial performance 
in heparinized rabbits. Acta Physiol Scand 153: 159-168, 1995. 
79. Holmuhamedov EL, Oberlin A, Short K, Terzic A, and Jahangir A. Cardiac 
Subsarcolemmal and Interfibrillar Mitochondria Display Distinct Responsiveness to 
Protection by Diazoxide. PLoS One 7: e44667, 2012. 
80. Hoppel CL, Moghaddas S, and Lesnefsky EJ. Interfibrillar cardiac 
mitochondrial comples III defects in the aging rat heart. Biogerontology 3: 41-44, 2002. 
40 
 
81. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, 
Lavoinne A, Hue L, Proud C, and Rider M. Activation of AMP-activated protein kinase 
leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. 
Curr Biol 12: 1419-1423, 2002. 
82. Houtkooper R and Vaz F. Cardiolipin, the heart of mitochondrial metabolism. 
Cellular and Molecular Life Sciences 65: 2493-2506, 2008. 
83. Hovius R, Lambrechts H, Nicolay K, and de Kruijff B. Improved methods to 
isolate and subfractionate rat liver mitochondria. Lipid composition of the inner and 
outer membrane. Biochim Biophys Acta 1021: 217-226, 1990. 
84. How OJ, Aasum E, Severson DL, Chan WY, Essop MF, and Larsen TS. 
Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. 
Diabetes 55: 466-473, 2006. 
85. Imai H and Nakagawa Y. Biological significance of phospholipid hydroperoxide 
glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic Biol Med 34: 
145-169, 2003. 
86. Indiveri C, Tonazzi A, Prezioso G, and Palmieri F. Kinetic characterization of 
the reconstituted carnitine carrier from rat liver mitochondria. Biochim Biophys Acta 
1065: 231-238, 1991. 
87. Jackson CV, McGrath GM, Tahiliani AG, Vadlamudi RV, and McNeill JH. A 
functional and ultrastructural analysis of experimental diabetic rat myocardium. 
Manifestation of a cardiomyopathy. Diabetes 34: 876-883, 1985. 
41 
 
88. Joost H-G, Al-Hasani H, Schurmann A, Bortell R, and Yang C. The BB Rat as 
a Model of Human Type 1 Diabetes. In: Animal Models in Diabetes Research: Humana 
Press, 2012, p. 31-44. 
89. Kadenbach B, Mende P, Kolbe HV, Stipani I, and Palmieri F. The 
mitochondrial phosphate carrier has an essential requirement for cardiolipin. FEBS Lett 
139: 109-112, 1982. 
90. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, Limana 
F, Nadal-Ginard B, Leri A, and Anversa P. IGF-1 overexpression inhibits the 
development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. 
Diabetes 50: 1414-1424, 2001. 
91. Kashihara H, Shi ZQ, Yu JZ, McNeill JH, and Tibbits GF. Effects of diabetes 
and hypertension on myocardial Na+-Ca2+ exchange. Can J Physiol Pharmacol 78: 12-
19, 2000. 
92. Kaul SC, Wadhwa R, Baseler W, Croston T, and Hollander J. Functional 
Characteristics of Mortalin. In: Mortalin Biology: Life, Stress and Death: Springer 
Netherlands, 2012, p. 55-80. 
93. Kikutani H and Makino S. The murine autoimmune diabetes model: NOD and 
related strains. Adv Immunol 51: 285-322, 1992. 
94. Kim J, Minkler PE, Salomon RG, Anderson VE, and Hoppel CL. Cardiolipin: 
characterization of distinct oxidized molecular species. Journal of Lipid Research, 2010. 
95. King C and Sarvetnick N. The incidence of type-1 diabetes in NOD mice is 
modulated by restricted flora not germ-free conditions. PLoS One 6: e17049, 2011. 
42 
 
96. King KL, Young ME, Kerner J, Huang H, O'Shea KM, Alexson SE, Hoppel 
CL, and Stanley WC. Diabetes or peroxisome proliferator-activated receptor alpha 
agonist increases mitochondrial thioesterase I activity in heart. J Lipid Res 48: 1511-
1517, 2007. 
97. Lesnefsky EJ, Chen Q, Slabe TJ, Stoll MSK, Minkler PE, Hassan MO, 
Tandler B, and Hoppel CL. Ischemia, rather than reperfusion, inhibits respiration 
through cytochrome oxidase in the isolated, perfused rabbit heart: role of cardiolipin. Am 
J Physiol Heart Circ Physiol 287: H258-267, 2004. 
98. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, and Hoppel CL. 
Mitochondrial dysfunction in cardiac disease: ischemia--reperfusion, aging, and heart 
failure. J Mol Cell Cardiol 33: 1065-1089, 2001. 
99. Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, and Ren J. Cardiac 
contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase 
activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and 
myosin heavy chain isozyme switch. Diabetologia 49: 1434-1446, 2006. 
100. Liu JE, Palmieri V, Roman MJ, Bella JN, Fabsitz R, Howard BV, Welty TK, 
Lee ET, and Devereux RB. The impact of diabetes on left ventricular filling pattern in 
normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 37: 
1943-1949, 2001. 
101. Lu B, Xu FY, Jiang YJ, Choy PC, Hatch GM, Grunfeld C, and Feingold KR. 
Cloning and characterization of a cDNA encoding human cardiolipin synthase (hCLS1). 
J Lipid Res 47: 1140-1145, 2006. 
43 
 
102. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, and Tochino Y. 
Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 29: 1-13, 1980. 
103. Mazumder PK, O'Neill BT, Roberts MW, Buchanan J, Yun UJ, Cooksey RC, 
Boudina S, and Abel ED. Impaired cardiac efficiency and increased fatty acid oxidation 
in insulin-resistant ob/ob mouse hearts. Diabetes 53: 2366-2374, 2004. 
104. McCormack JG and Denton RM. Mitochondrial Ca2+ transport and the role of 
intramitochondrial Ca2+ in the regulation of energy metabolism. Dev Neurosci 15: 165-
173, 1993. 
105. Mirsky I. Assessment of diastolic function: suggested methods and future 
considerations. Circulation 69: 836-841, 1984. 
106. Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, Winegar DA, 
Corton JC, Dohm GL, and Kraus WE. Fatty acid homeostasis and induction of lipid 
regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor 
(PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. J 
Biol Chem 277: 26089-26097, 2002. 
107. Nalecz KA, Bolli R, Wojtczak L, and Azzi A. The monocarboxylate carrier from 
bovine heart mitochondria: partial purification and its substrate-transporting properties in 
a reconstituted system. Biochim Biophys Acta 851: 29-37, 1986. 
108. Neupert W and Herrmann JM. Translocation of proteins into mitochondria. 
Annu Rev Biochem 76: 723-749, 2007. 
109. Nichols GA, Hillier TA, Erbey JR, and Brown JB. Congestive heart failure in 
type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24: 1614-1619, 
2001. 
44 
 
110. Nielsen J, Mogensen M, Vind BF, Sahlin K, Hojlund K, Schroder HD, and 
Ortenblad N. Increased subsarcolemmal lipids in type 2 diabetes: effect of training on 
localization of lipids, mitochondria, and glycogen in sedentary human skeletal muscle. 
Am J Physiol Endocrinol Metab 298: E706-713, 2010. 
111. Nishimura RA and Tajik AJ. Evaluation of diastolic filling of left ventricle in 
health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am 
Coll Cardiol 30: 8-18, 1997. 
112. Ohtake T, Yokoyama I, Watanabe T, Momose T, Serezawa T, Nishikawa J, 
and Sasaki Y. Myocardial glucose metabolism in noninsulin-dependent diabetes 
mellitus patients evaluated by FDG-PET. J Nucl Med 36: 456-463, 1995. 
113. Oliveira PJ, Seica R, Coxito PM, Rolo AP, Palmeira CM, Santos MS, and 
Moreno AJ. Enhanced permeability transition explains the reduced calcium uptake in 
cardiac mitochondria from streptozotocin-induced diabetic rats. FEBS Lett 554: 511-
514, 2003. 
114. Oliveira PJ, Seica R, Santos DL, Rolo AP, Sardao VA, Ferreira FM, Palmeira 
CM, Santos MS, and Moreno AJ. Vitamin E or coenzyme Q10 administration is not 
fully advantageous for heart mitochondrial function in diabetic goto kakizaki rats. 
Mitochondrion 3: 337-345, 2004. 
115. Orrenius S, Gogvadze V, and Zhivotovsky B. Mitochondrial oxidative stress: 
implications for cell death. Annu Rev Pharmacol Toxicol 47: 143-183, 2007. 
116. Palmer JW, Tandler B, and Hoppel CL. Biochemical properties of 
subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. Journal 
of Biological Chemistry 252: 8731-8739, 1977. 
45 
 
117. Paradise NF, Pilati CF, Payne WR, and Finkelstein JA. Left ventricular 
function of the isolated, genetically obese rat's heart. Am J Physiol 248: H438-444, 
1985. 
118. Penpargkul S, Schaible T, Yipintsoi T, and Scheuer J. The effect of diabetes 
on performance and metabolism of rat hearts. Circ Res 47: 911-921, 1980. 
119. Petrosillo G, Ruggiero FM, and Paradies G. Role of reactive oxygen species 
and cardiolipin in the release of cytochrome c from mitochondria. FASEB J 17: 2202-
2208, 2003. 
120. Rabol R, Boushel R, and Dela F. Mitochondrial oxidative function and type 2 
diabetes. Appl Physiol Nutr Metab 31: 675-683, 2006. 
121. Regan TJ, Ettinger PO, Khan MI, Jesrani MU, Lyons MM, Oldewurtel HA, 
and Weber M. Altered Myocardial Function and Metabolism in Chronic Diabetes 
Mellitus without Ischemia in Dogs. Circulation Research 35: 222-237, 1974. 
122. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, 
and Haider B. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 
60: 884-899, 1977. 
123. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, and Kelley DE. 
Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 54: 
8-14, 2005. 
124. Riva A, Tandler B, Loffredo F, Vazquez E, and Hoppel C. Structural 
differences in two biochemically defined populations of cardiac mitochondria. Am J 
Physiol Heart Circ Physiol 289: H868-872, 2005. 
46 
 
125. Robertson RP and Harmon JS. Diabetes, glucose toxicity, and oxidative stress: 
A case of double jeopardy for the pancreatic islet [beta] cell. Free Radical Biology and 
Medicine 41: 177-184, 2006. 
126. Rodrigues B and McNeill JH. Cardiac dysfunction in isolated perfused hearts 
from spontaneously diabetic BB rats. Can J Physiol Pharmacol 68: 514-518, 1990. 
127. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, 
Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, 
Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, 
Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, 
Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, 
Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner 
MB, Wong ND, and Wylie-Rosett J. Heart Disease and Stroke Statistics - 2011 
Update Circulation 123: e18-e209. 
128. Rolo AP and Palmeira CM. Diabetes and mitochondrial function: Role of 
hyperglycemia and oxidative stress. Toxicology and Applied Pharmacology 212: 167-
178, 2006. 
129. Rolo AP and Palmeira CM. Diabetes and mitochondrial function: role of 
hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 212: 167-178, 2006. 
130. Rosca MG, Vazquez EJ, Kerner J, Parland W, Chandler MP, Stanley W, 
Sabbah HN, and Hoppel CL. Cardiac mitochondria in heart failure: decrease in 
respirasomes and oxidative phosphorylation. Cardiovasc Res 80: 30-39, 2008. 
47 
 
131. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, and Grishman 
A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J 
Cardiol 30: 595-602, 1972. 
132. Santos DL, Palmeira CM, Seiccedila R, Dias J, Mesquita J, Moreno AJ, and 
Santos MS. Diabetes and mitochondrial oxidative stress: A study using heart 
mitochondria from the diabetic Goto-Kakizaki rat. Molecular and Cellular Biochemistry 
246: 163-170, 2003. 
133. Schlame M, Rua D, and Greenberg ML. The biosynthesis and functional role of 
cardiolipin. Prog Lipid Res 39: 257-288, 2000. 
134. Scognamiglio R, Avogaro A, Negut C, Piccolotto R, Vigili de Kreutzenberg 
S, and Tiengo A. Early myocardial dysfunction in the diabetic heart: current research 
and clinical applications. Am J Cardiol 93: 17A-20A, 2004. 
135. Sedlak E and Robinson NC. Phospholipase A(2) digestion of cardiolipin bound 
to bovine cytochrome c oxidase alters both activity and quaternary structure. 
Biochemistry 38: 14966-14972, 1999. 
136. Severson DL. Diabetic cardiomyopathy: recent evidence from mouse models of 
type 1 and type 2 diabetes. Can J Physiol Pharmacol 82: 813-823, 2004. 
137. Shen X, Zheng S, Metreveli NS, and Epstein PN. Protection of cardiac 
mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 
55: 798-805, 2006. 
138. Shen X, Zheng S, Thongboonkerd V, Xu M, Pierce WM, Jr., Klein JB, and 
Epstein PN. Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 
diabetes. Am J Physiol Endocrinol Metab 287: E896-905, 2004. 
48 
 
139. Singh B, Patel HV, Ridley RG, Freeman KB, and Gupta RS. Mitochondrial 
import of the human chaperonin (HSP60) protein. Biochem Biophys Res Commun 169: 
391-396, 1990. 
140. Singh VP, Le B, Khode R, Baker KM, and Kumar R. Intracellular angiotensin II 
production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, 
and cardiac fibrosis. Diabetes 57: 3297-3306, 2008. 
141. Solano MP and Goldberg RB. Lipid Management in Type 2 Diabetes. Clinical 
Diabetes 24: 27-32, 2006. 
142. Song Y, Du Y, Prabhu SD, and Epstein PN. Diabetic Cardiomyopathy in 
OVE26 Mice Shows Mitochondrial ROS Production and Divergence Between In Vivo 
and In Vitro Contractility. Rev Diabet Stud 4: 159-168, 2007. 
143. Stanley WC and Hoppel CL. Mitochondrial dysfunction in heart failure: potential 
for therapeutic interventions? Cardiovascular Research 45: 805-806, 2000. 
144. Struthers AD and Morris AD. Screening for and treating left-ventricular 
abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359: 
1430-1432, 2002. 
145. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of 
the rat pancreas. Physiol Res 50: 537-546, 2001. 
146. Takenaka K, Sakamoto T, Amano K, Oku J, Fujinami K, Murakami T, Toda I, 
Kawakubo K, and Sugimoto T. Left ventricular filling determined by Doppler 
echocardiography in diabetes mellitus. Am J Cardiol 61: 1140-1143, 1988. 
49 
 
147. Tomita M, Mukae S, Geshi E, Umetsu K, Nakatani M, and Katagiri T. 
Mitochondrial respiratory impairment in streptozotocin-induced diabetic rat heart. Jpn 
Circ J 60: 673-682, 1996. 
148. Torok Z, Demel RA, Leenhouts JM, and de Kruijff B. Presequence-mediated 
intermembrane contact formation and lipid flow. A model membrane study. Biochemistry 
33: 5589-5594, 1994. 
149. Turko IV, Li L, Aulak KS, Stuehr DJ, Chang JY, and Murad F. Protein tyrosine 
nitration in the mitochondria from diabetic mouse heart. Implications to dysfunctional 
mitochondria in diabetes. J Biol Chem 278: 33972-33977, 2003. 
150. Turko IV and Murad F. Quantitative protein profiling in heart mitochondria from 
diabetic rats. J Biol Chem 278: 35844-35849, 2003. 
151. Vadlamudi RV, Rodgers RL, and McNeill JH. The effect of chronic alloxan- and 
streptozotocin-induced diabetes on isolated rat heart performance. Can J Physiol 
Pharmacol 60: 902-911, 1982. 
152. Vadvalkar SS, Baily CN, Matsuzaki S, West M, Tesiram YA, and Humphries 
KM. Metabolic inflexibility and protein lysine acetylation in heart mitochondria of a 
chronic model of type 1 diabetes. Biochem J 449: 253-261, 2013. 
153. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, and Telser J. Free 
radicals and antioxidants in normal physiological functions and human disease. The 
International Journal of Biochemistry & Cell Biology 39: 44-84, 2007. 
154. van de Weijer T, Schrauwen-Hinderling VB, and Schrauwen P. Lipotoxicity in 
type 2 diabetic cardiomyopathy. Cardiovascular Research 92: 10-18, 2011. 
50 
 
155. Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter 
U, Fischer JW, Bohm M, Pauschinger M, Schultheiss HP, and Tschope C. Reduced 
MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. 
Basic Res Cardiol 103: 319-327, 2008. 
156. Voos W, Martin H, Krimmer T, and Pfanner N. Mechanisms of protein 
translocation into mitochondria. Biochim Biophys Acta 1422: 235-254, 1999. 
157. Weinstein ES, Benson DW, and Fry DE. Subpopulations of human heart 
mitochondria. Journal of Surgical Research 40: 495-498, 1986. 
158. Weiss JS and Sumpio BE. Review of prevalence and outcome of vascular 
disease in patients with diabetes mellitus. Eur J Vasc Endovasc Surg 31: 143-150, 
2006. 
159. Wende AR and Abel ED. Lipotoxicity in the heart. Biochimica et Biophysica Acta 
(BBA) - Molecular and Cell Biology of Lipids 1801: 311-319, 2010. 
160. Whalen BJ, Mordes JP, and Rossini AA. The BB Rat as a Model of Human 
Insulin-Dependent Diabetes Mellitus. In: Current Protocols in Immunology: John Wiley & 
Sons, Inc., 2001. 
161. Wild S, Roglic G, Green A, Sicree R, and King H. Global prevalence of 
diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-
1053, 2004. 
162. Williamson CL, Dabkowski ER, Baseler WA, Croston TL, Alway SE, and 
Hollander JM. Enhanced apoptotic propensity in diabetic cardiac mitochondria: 
influence of subcellular spatial location. Am J Physiol Heart Circ Physiol 298: H633-642, 
2010. 
51 
 
163. Williamson CL, Dabkowski ER, Dillmann WH, and Hollander JM. 
Mitochondria protection from hypoxia/reoxygenation injury with mitochondria heat shock 
protein 70 overexpression. Am J Physiol Heart Circ Physiol 294: H249-256, 2008. 
164. Wright JJ, Kim J, Buchanan J, Boudina S, Sena S, Bakirtzi K, Ilkun O, 
Theobald HA, Cooksey RC, Kandror KV, and Abel ED. Mechanisms for increased 
myocardial fatty acid utilization following short-term high-fat feeding. Cardiovasc Res 
82: 351-360, 2009. 
165. Wu KK and Huan Y. Streptozotocin-Induced Diabetic Models in Mice and Rats. 
In: Current Protocols in Pharmacology: John Wiley & Sons, Inc., 2001. 
166. Yang R and Barouch LA. Leptin Signaling and Obesity: Cardiovascular 
Consequences. Circulation Research 101: 545-559, 2007. 
167. Ye G, Metreveli NS, Ren J, and Epstein PN. Metallothionein prevents diabetes-
induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. 
Diabetes 52: 777-783, 2003. 
168. Yoshioka M, Kayo T, Ikeda T, and Koizumi A. A novel locus, Mody4, distal to 
D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 
(Akita) mutant mice. Diabetes 46: 887-894, 1997. 
169. Young ME, Guthrie PH, Razeghi P, Leighton B, Abbasi S, Patil S, Youker 
KA, and Taegtmeyer H. Impaired long-chain fatty acid oxidation and contractile 
dysfunction in the obese Zucker rat heart. Diabetes 51: 2587-2595, 2002. 
170. Yue P, Arai T, Terashima M, Sheikh AY, Cao F, Charo D, Hoyt G, Robbins 
RC, Ashley EA, Wu J, Yang PC, and Tsao PS. Magnetic resonance imaging of 
52 
 
progressive cardiomyopathic changes in the db/db mouse. Am J Physiol Heart Circ 
Physiol 292: H2106-2118, 2007. 
171. Zarich SW, Arbuckle BE, Cohen LR, Roberts M, and Nesto RW. Diastolic 
abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler 
echocardiography. J Am Coll Cardiol 12: 114-120, 1988. 
172. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, and Friedman JM. 
Positional cloning of the mouse obese gene and its human homologue. Nature 372: 
425-432, 1994. 
 
 
Chapter 2: 
 
Evaluation of the cardiolipin biosynthetic pathway and its interactions in the 
diabetic heart 
 
As accepted in Life Sciences, 2013 July 
 
 
Tara L. Croston1, Danielle L. Shepherd1, Dharendra Thapa1, Cody E. Nichols1, Sara E. 
Lewis1, Erinne R. Dabkowski1, Rajaganapathi Jagannathan1, Walter A. Baseler1, and 
John M. Hollander1 
 
 
1West Virginia University School of Medicine, Division of Exercise Physiology; Center 
for Cardiovascular and Respiratory Sciences; Morgantown, WV 26506 
 
 
 
Running Title: Cardiolipin Biosynthesis in the Diabetic Heart 
54 
 
ABSTRACT 
Aims: We have previously reported alterations in cardiolipin content and inner 
mitochondrial membrane (IMM) proteomic make-up specifically in interfibrillar 
mitochondria (IFM) in the type 1 diabetic heart; however, the mechanism underlying this 
alteration is unknown. The goal of this study was to determine how the cardiolipin 
biosynthetic pathway and cardiolipin-IMM protein interactions are impacted by type 1 
diabetes mellitus.  
Main methods: Male FVB mice were made diabetic by multiple low-dose streptozotocin 
injections and sacrificed five weeks post-diabetic onset. Messenger RNA was measured 
and cardiac mitochondrial subpopulations were isolated. Further mitochondrial 
functional experimentation included evaluating the protein expression of the enzymes 
directly responsible for cardiolipin biosynthesis, as well as ATP synthase activity. 
Interactions between cardiolipin and ATP synthase subunits were also examined. 
Key findings: Western blot analysis revealed a significant decrease of cardiolipin 
synthase (CRLS) protein content in diabetic IFM, with a concomitant decrease in its 
activity. ATP synthase activity was also significantly decreased. We identified two novel 
direct interactions between two subunits of the ATP synthase F0 complex (ATP5F1 and 
ATP5H), both of which were significantly decreased in diabetic IFM.  
Significance: Overall, these results indicate that type 1 diabetes mellitus negatively 
impacts the cardiolipin biosynthetic pathway specifically at CRLS, contributing to 
decreased cardiolipin content and loss of interactions with key ATP synthase F0 
complex constituents in the IFM.  
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INTRODUCTION 
 
Cardiovascular complications are the primary cause of morbidity in diabetic 
patients, of which diabetic cardiomyopathy has been associated with mitochondrial 
dysfunction (10, 28, 31). The inner mitochondria membrane (IMM) houses vital 
processes in a specific lipid environment. Alteration in the IMM lipid environment has 
been associated with dysfunction to mitochondrial processes (1, 6, 14, 18). Proteomic 
analyses of type 1 diabetic mitochondria indicates that IMM proteins may be particularly 
prone to damage and loss (3).  
 
Impaired mitochondrial function, particularly in those processes situated in the 
IMM, may be associated with disruption to the phospholipid environment contained 
within. Most abundant in the mammalian heart, cardiolipin is a unique phospholipid, 
primarily located in the IMM (26) and is thought to play a critical role in mitochondrial 
structure and bioenergetics (1). The biosynthetic pathway (Figure 2.1) begins in the 
outer mitochondrial membrane where phosphatidic acid is converted into cytidine 
diphosphate diacylglycerol (CDP-DAG) by cytidine diphosphate diacylglycerol synthase 
(CDS) (17). Phosphatidylglycerol synthase (PGS) then converts CDP-DAG to 
phosphatidylglycerol phosphate (PG-P), where the phosphate is removed by 
phosphatidylglycerol phosphatase (PGP), resulting in the formation of 
phosphatidylglycerol (PG). Cardiolipin synthase (CRLS) then catalyzes the 
condensation of CDP-DAG and PG, resulting in a nascent form of cardiolipin (6, 21). 
Because the nascent cardiolipin does not contain the precise fatty acyl side chains for 
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the specific tissue, a remodeling process takes place, where tafazzin (TAZ) or 
monolysocardiolipin acyltransferase, converts the nascent cardiolipin to mature 
cardiolipin containing specific fatty acyl side chains (6), which is dependent upon the 
tissue and environment. Linoleic acid, the most abundant fatty acid found in cardiac 
mitochondria, constitutes approximately 80% of all side chains (2, 26). The properties of 
cardiolipin allow it to interact with IMM proteins and facilitate proper mitochondrial 
function.  
 
Literature suggests an interaction between cardiolipin and the electron transport 
chain (ETC) complexes involved in oxidative phosphorylation (26), including complexes 
I, III, IV, and ATP synthase (12, 27). Cardiolipin plays a critical role in the organization of 
mammalian mitochondrial ATP synthase and it has been suggested that the F0 complex 
of ATP synthase contains high affinity binding sites for cardiolipin (1); however, the 
specific binding sites remain undefined. Cardiolipin also serves as a proton reservoir for 
maintenance of IMM potential thus, contributing to ATP synthesis (13). Shotgun 
lipidomics revealed decreased tetralinoleic cardiolipin content in diabetic hearts 
suggesting a possible mechanistic reliance on the interaction between IMM protein 
activity and cardiolipin (14). We have previously reported decreased ETC protein 
content and function in IFM following a type 1 diabetic insult (3, 8), correlating with 
decreased tetralinoleic cardiolipin content, with no effect on subsarcolemmal 
mitochondria (SSM) situated beneath the plasma membrane (8). 
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To date, the impact of type 1 diabetes mellitus on the cardiolipin biosynthetic 
pathway in mitochondrial subpopulations and on the interactions between cardiolipin 
and IMM proteins has not been studied. We hypothesized that the decreased cardiolipin 
content associated with type 1 diabetes mellitus results from defective cardiolipin 
biosynthesis influencing its association with IMM proteins, with the effects being most 
pronounced in IFM.  
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MATERIALS AND METHODS 
 
Experimental animals and induction of diabetes 
The animal experiments in this study conformed to the National Institutes of 
Health (NIH) Guidelines for the Care and Use of Laboratory Animals and were approved 
by the West Virginia University Animal Care and Use Committee. Male FVB mice were 
housed in the West Virginia University Health Sciences Center animal facility on a 12-
hr light/dark cycle in a temperature controlled room. Mice were given unlimited access 
to a standard rodent diet and water. Type 1 diabetes mellitus was induced in 6-week-old 
mice following the protocol of the Animal Models of Diabetic Complications Consortium 
using multiple low-dose streptozotocin (STZ; Sigma-Aldrich Corporation, St. Louis, MO) 
intraperitoneal injections. The STZ-induced type 1 diabetic model was chosen because 
it is the most widely utilized model and the multiple low dose administration is not 
associated with many of the deleterious side effects observed with the single high-dose 
approach  (34). Injections of 50 mg/kg body weight STZ dissolved in sodium citrate 
buffer (pH 4.5) were performed daily for 5 consecutive days after 6 hours of fasting. 
Mice serving as vehicle controls were given the same volume per body weight of 
sodium citrate buffer. One week post-injection, hyperglycemia was confirmed by 
measuring blood glucose (Contour Blood Glucose test strips; Bayer, Mishawaka, IN), 
where > 250 mg/dL was considered diabetic. Five weeks after the onset of 
hyperglycemia, animals were sacrificed for experimentation. Blood glucose levels were 
again tested at this time and all remained > 250 mg/dL. 
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Individual Mitochondrial Subpopulations Isolation 
 Five weeks post-diabetic onset, FVB mice and their littermate controls were 
sacrificed and hearts excised. Hearts were rinsed in phosphate buffered saline (PBS, 
pH 7.4), then blotted dry. SSM and IFM were isolated as previously described by 
Palmer et al. (25) with modifications by our laboratory (8, 9, 33). Mitochondrial pellets 
were resuspended in either KME buffer (100 mM KCl, 50 mM MOPS, and 0.5 mM 
EDTA) for Western blot analysis and activity measurements, or in 1.0% NP-40 
wash/binding buffer (10 mM HEPES (pH 7.4), 1.0% NP-40, 150 mM NaCl) for 
cardiolipin/protein interactions. Protein content was determined by the Bradford method 
using bovine serum albumin as a standard (4). 
 
Cardiolipin 
Isolated mitochondrial subpopulations from control and diabetic hearts were 
pooled, and sent off to Avanti Polar Lipids, Inc. (Alabaster, AL) for cardiolipin analysis. 
Extraction and analysis of cardiolipin species were based on the protocols of Sparagna 
et al. (29) and Minkler et al. (23). In brief, cardiolipin detection was performed by liquid 
chromatography (Dionex U-3000 binary HPLC) / hybrid tandem mass spectrometry 
using a quadrapole -linear ion trap (API 4000 Qtrap) operated in the negative ion mode. 
Mass spectrometer instrument conditions included a spray voltage of -4.5 kV, capillary 
voltage of -150 V, heated capillary temperature of 400°C, and a sheath gas flow rate of 
10 arbitrary units. Mitochondrial cardiolipin and internal standard spectra were identified 
by multiple reaction monitoring. All experiments were performed in triplicate. 
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mRNA Isolation and analysis 
mRNA levels were examined as previously described (3). Briefly, hearts were 
rinsed in phosphate buffered saline (PBS, pH 7.4) then snap frozen in liquid nitrogen. 
Thirty milligrams of tissue was excised from control and diabetic hearts from which the 
mRNA was extracted using an RNeasy mini kit, per manufacturer’s instructions 
(Qiagen, Valencia, CA) and reverse transcribed. Equal amounts of cDNA from the 
hearts of control and diabetic mice were subjected to real-time PCR. Custom primers 
were designed for target genes CDS, PGS, CRLS, and TAZ. SYBR Green I was used 
for quantification of respective cDNA replicates (Qiagen, Velencia, CA). Data were 
normalized by gene expression relative to the levels of GAPDH. 
 
Western Blot Analyses 
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was 
run on a 4-12% gel as previously described (20, 33) with equal amounts of protein 
loaded for each study treatment.  Relative amounts of subpopulation-specific CDS, 
PGS, CRLS, and TAZ, were assessed using the following primary antibodies; anti-CDS 
rabbit antibody (product No. ab84019, Abcam, Cambridge, MA), anti-PGS rabbit 
antibody (product No. ab104815, Abcam, Cambridge, MA), anti-CRLS rabbit antibody 
(product No. 49444_P050, Aviva Systems Biology, San Diego, CA), and anti-TAZ rabbit 
antibody (product No. ab84927, Abcam, Cambridge, MA).  The secondary antibody 
used was a goat anti-rabbit IgG horseradish peroxidase conjugate (product No. 
10004301, Cayman Chemical Company, Ann Arbor, MI).  Detection of signal was 
performed according to the Pierce ECL Western Blotting Substrate detection system 
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manufacturer’s directions (Thermo Fisher Scientific Inc., Rockford, IL).  Cytochrome c 
oxidase (COX IV) was used to control for protein loading (product No. ab16056, Abcam, 
Cambridge, MA). Quantification of chemiluminescent signals were assessed using a 
G:Box Bioimaging System (Syngene, Frederick, MD), and the data captured using 
GeneSnap software (Syngene, Frederick, MD). Densitometry was measured using 
Image J Software (National Institutes of Health, Bethesda, MD). 
 
Cardiolipin Synthase (CRLS) Activity 
CRLS activity was assessed as previously described (5) with minor 
modifications. Briefly, a reaction mixture containing 20 μM 14C-oleoyl-CoA (50 
mCi/mmol; American Radiolabeled Chemicals, Inc, MO), 2.0 mM LPG [1-oleoyl-2-
hydroxy-sn-glycero-3-[phospho-rac-(1-glycerol)]] and 2.0 mM CDP-DAG (Avanti Polar 
Lipids Inc., Alabaster, AL) were incubated with 50 μg of lysed mitochondrial protein for 
30 min at 37°C. The reactions were terminated by adding chloroform/methanol, followed 
by a quick vortex, then chloroform, followed by a quick vortex and lastly, 0.1 M KCl to 
facilitate phase separation. A brief centrifugation was performed to extract lipids. The 
organic phase was collected, dried under an argon stream and separated by high 
performance thin layer chromatography plates (Whatman, GE Healthcare, U.S.A) with 
chloroform/hexane/methanol/acetic acid (25:15:5:2.5 by volume) as the developing 
solvent. The high performance thin layer chromatography plates are then stained with 
iodine vapor.  The appropriate lipid spots are scraped off the plate and dissolved in 
scintillation fluid for scintillation counting. 
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ATP Synthase Activity  
Activity was measured in control and diabetic mitochondrial subpopulations as 
oligomycin-sensitive ATPase activity using an assay coupled with pyruvate kinase 
which converts the ADP to ATP and produces pyruvate from phosphoenolpyruvate as 
previously described (7). Protein content was assessed as described above (4) with 
final values expressed as nanomoles of NADH per minute per milligram of protein, 
equal to the nanomoles of NADH oxidized per minute per milligram of protein.   
 
Lipid-Protein Interaction 
Cardiolipin-coated beads (Product No. P-BCLP, Echelon Biosciences 
Incorporated, Salt Lake City, UT) were used to determine protein interactions with 
cardiolipin per the manufacturer’s instructions. In brief, 100 µl of cardiolipin-coated 
beads were incubated with 600 µg mitochondrial protein diluted in 1.0% NP-40 
wash/binding buffer overnight at 4°C. The beads were spun down at 800 x g. The 
supernatant containing the unbound proteins was collected and the beads were washed 
four times with 10x excess of wash/binding buffer. The proteins bound to the beads 
were eluted with 4x Laemmli sample buffer and heated to 95°C. A Western blot was 
then performed on the eluted protein from the beads and the unbound protein located in 
the supernatant using the following specific antibodies: anti-ATP5F1 mouse antibody 
(product No. ab117991, Abcam, Cambridge, MA), anti-ATP5H mouse antibody (product 
No. ab110275, Abcam, Cambridge, MA), anti-ATPB mouse antibody (product No. 
ab14730, Abcam, Cambridge, MA), anti-ATP5A (product No. ab110273, Abcam, 
Cambridge, MA), and anti-GRP75 rabbit antibody (product No. 2816S, Cell Signaling 
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Technology, Danvers, MA). The secondary antibodies used were either a goat anti-
rabbit IgG horseradish peroxidase conjugate (product No. 10004301, Cayman Chemical 
Company, Ann Arbor, MI) or a goat anti-mouse IgG horseradish peroxidase conjugate 
(product No. 31430, Thermo Fisher Scientific Inc., Rockford, IL). Detection of signal was 
performed according to the Pierce ECL Western Blotting Substrate detection system 
manufacturer’s directions (Thermo Fisher Scientific Inc., Rockford, IL). Quantification of 
chemiluminescent signals were assessed using a G:Box Bioimaging System (Syngene, 
Frederick, MD), and the data captured using GeneSnap software (Syngene, Frederick, 
MD) as above. Densitometry was measured using Image J Software (National Institutes 
of Health, Bethesda, MD) as above. The association between cardiolipin and the 
mitochondrial protein of interest was determined by using the densitometric ratio of the 
protein bound to native cardiolipin/protein bound to native cardiolipin + protein bound to 
the cardiolipin-coated beads. 
 
Statistics  
Means and SEMs were calculated for all data sets. Data were analyzed using a 
Student’s t-test (GraphPad Software Inc., La Jolla, CA). Differences between control 
and diabetic groups were considered statistically significant when a P < 0.05 was 
observed.  
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RESULTS 
 
Cardiolipin Content in the Diabetic Heart 
Han et al. (14) indicated an overall decrease in cardiolipin content in the diabetic 
heart and our laboratory has previously reported decreased tetralinoleic cardiolipin 
content in the diabetic IFM (8). Because CRLS synthesizes the nascent form of 
cardiolipin, total cardiolipin content was measured. The cardiolipin content in the IFM 
significantly decreased from 84.46 + 1.93 nmol/mg of protein in the control heart to 
48.75 + 2.83 nmol/mg of protein in the diabetic heart, with no difference in the SSM 
(44.99 + 1.75 nmol/mg of protein in control heart compared to 37.87 + 0.11 nmol/mg of 
protein in diabetic heart); therefore, we hypothesized that the decrease in cardiolipin 
may be caused by an alteration in the cardiolipin biosynthetic pathway during a diabetic 
insult. 
 
mRNA Analyses of Cardiolipin Biosynthesis Pathway Constituents 
To gain insight into the impact of diabetes mellitus on transcriptional regulation of 
the enzymatic components of the cardiolipin biosynthetic pathway, the mRNA levels of 
three constituent enzymes, CDS, PGS, and CRLS, as well as the remodeling enzyme 
TAZ, were analyzed. The results indicated no significant differences between control 
and diabetic heart for any of the constituents responsible for cardiolipin biosynthesis or 
remodeling (Table 2.1). These results suggest that the observed decreased in IFM 
cardiolipin content resulting from a type 1 diabetic insult does not occur at the 
transcriptional level. 
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The expression levels of other IMM proteins were also listed in Table 1. None of 
the mRNA levels of proteins involved in protein import were altered in a diabetic heart. 
Of all the transcripts involved in oxidative phosphorylation, only electron transfer 
flavoprotein-ubiquinone oxidoreductase was significantly decreased in the diabetic. This 
protein is responsible for the transferring of electrons to the mitochondrial respiratory 
chain. This decrease suggests a reduction in the electron flux through the respiratory 
chain, which could potentially cause decreased oxidative phosphorylation. This potential 
result is supported by decreased mitochondrial respiration in the presence of type 1 
diabetes mellitus reported by our laboratory (Dabkowski et al. 2009).  
 
Protein Analyses of Cardiolipin Biosynthesis Pathway Constituents 
To determine the impact of diabetes mellitus on translational regulation of the 
enzymatic components of the cardiolipin biosynthetic pathway, the protein levels of 
three constituent enzymes, CDS, PGS, and CRLS, as well as the remodeling enzyme 
TAZ, were analyzed. Western blot analyses revealed a significant decrease only in 
CRLS protein content in diabetic IFM as compared to control, with no impact on CRLS 
protein content in the SSM (Figures 2.2E and 2.2F).  No significant differences were 
observed in the protein levels of the other cardiolipin biosynthetic enzymes assessed, 
regardless of subpopulation (Figure 2.2). It is important to note that CDS-2 is the major 
isoform in the heart and when the protein expression was measured, there was no 
difference between the two treatment groups for either subpopulation (data not shown). 
These results indicate that the observed decrease in IFM cardiolipin content resulting 
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from a type 1 diabetic insult is associated with a decrease in the protein content of 
CRLS, and thus the biosynthetic pathway. 
 
Enzymatic Activity Analyses of CRLS 
Because CRLS protein content was the only change observed in the biosynthetic 
pathway following a diabetic insult, we investigated the impact of diabetes mellitus on 
CRLS enzymatic activity using an assay that utilizes 14C-oleoyl-coenzyme A as an acyl 
donor. 14C-oleoyl-coenzyme A lipid was incubated with additional compounds and 
mitochondrial protein then subjected to high performance thin layer chromatography.  
Our results revealed a decrease in CRLS activity in diabetic IFM as compared to control 
(Figure 2.3B), with no change in the SSM (Figure 2.3A). During high performance thin 
layer chromatography, PG runs below cardiolipin, so as a control to ensure that the 
assay was only affecting the radioactivity incorporated into cardiolipin, the amount of 
radioactivity incorporated into PG was also measured through scintillation counting. The 
results indicated no change in 14C-PG in diabetic mitochondria relative to control for 
either subpopulation (Figures 2.3C and 2.3D). These results complement the CRLS 
proteomic data and suggest that loss of CRLS protein in the IFM results in a decrease 
in CRLS enzymatic activity. 
 
ATP Synthase Activity Analyses 
Literature suggests that cardiolipin interacts with components of the ATP 
synthase complex (1, 11); however, these interaction sites are unknown. Further, 
previous proteomic data from our laboratory indicates that ATP synthase components 
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are decreased in diabetic IFM (3). As a result, we determined whether the activity of the 
ATP synthase complex was impacted in diabetic mitochondria. Our analyses indicated 
that ATP synthase activity was significantly decreased in the diabetic IFM as compared 
to control (Figure 2.4B) with no differences observed in the SSM subpopulation (Figure 
2.4A). These results suggest that the decrease in ATP synthase activity observed in 
diabetic IFM is associated with a decrease in cardiolipin content, which may be 
influencing its functional properties. 
 
Cardiolipin and ATP Synthase Interaction 
To gain insight into which ATP synthase constituent proteins may be interacting 
with cardiolipin, we developed an approach in which we incubated cardiolipin-coated 
beads with mitochondrial proteins and probed for the interaction.  Figure 2.5A and 2.5B 
demonstrates direct association of cardiolipin with ATP synthase subunit b (ATP5F1) 
and ATP synthase subunit d (ATP5H), both of which are subunits of the F0 complex, or 
proton pore, of the ATP synthase. To validate that the cardiolipin-coated beads were 
specifically binding to proteins that interact with cardiolipin, interactions of proteins not 
associated with cardiolipin were examined. First, ATP synthase alpha (ATP5A) and ATP 
synthase beta (ATPB) were measured. The results indicated that neither protein was 
interacting with the cardiolipin-coated beads (Figures 2.5C and 2.5D, respectively). 
Next, glucose regulated protein 75 (GRP75), a protein located in the mitochondrial 
matrix, was examined. The results indicated the absence of GRP75 bound to the 
cardiolipin-coated beads in both subpopulations (Figures 2.5E and 2.5F, respectively).  
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Once the interactions between the aforementioned ATP synthase subunits and 
cardiolipin were detected, we quantified the association between the lipid and protein 
that occurs in the mitochondrion during a diabetic insult. By assessing proteins that are 
associated with native cardiolipin, which are incapable of binding to the coated beads 
(native bound), as well as those proteins that can bind to the beads (bead bound), we 
were able to determine how diabetes mellitus impacts cardiolipin association with these 
two proteins.  Figure 2.6A represents the protein content of ATP5F1 in the different 
mitochondrial subpopulations of control and diabetic hearts, respectively, while Figure 
2.6B represents the protein content of ATP5H. In order to quantify the associations of 
ATP synthase subunits and native cardiolipin, the optical density of the band that 
resulted from the protein interacting with native cardiolipin (native bound protein) was 
divided by the optical density of the bands that resulted from both the protein bound to 
native cardiolipin (native bound) and the protein bound to the cardiolipin-coated beads 
(bead bound). This ratio was used to quantify the interactions of cardiolipin with the 
protein in control and diabetic mitochondrial subpopulations. The results indicated no 
difference in the associations between cardiolipin and ATP5F1 or ATP5H in the diabetic 
SSM compared to controls (Figures 2.6C and 2.6D, respectively). Interestingly, a 
significant decrease in the interactions between native cardiolipin and both ATP5F1 and 
ATP5H in diabetic IFM, as compared to control, was observed (Figures 2.6E and 2.6F, 
respectively). 
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DISCUSSION 
 
Mitochondrial dysfunction is an underlying contributor to diabetic cardiomyopathy 
(10, 28, 31). The IMM is an important submitochondrial locale which houses the 
machinery required for a number of mitochondrial functional processes. When the lipid 
environment of the IMM is altered, the processes contained within can become impaired 
(1, 6, 14, 18). Cardiolipin, makes up approximately 20% of the total IMM phospholipid 
membrane (32) and is required for proper functioning of a number of mitochondrial 
processes (6, 12, 18).  In this study, we observed a decrease in total cardiolipin content 
in the diabetic IFM. Our laboratory has previously reported significant decreases in 
tetralinoleic cardiolipin content of diabetic IFM, as well as loss of a number of proteins 
that are constituents for crucial functional processes (3, 8). These results are further 
supported by others who have reported decreased total cardiolipin content 28 days after 
the induction of diabetes mellitus (14), as well as decreased tetralinoleic cardiolipin in 
diabetic mouse hearts compared to control days after the induction of diabetes mellitus 
(15). Thus, our hypothesis for the current study centered on understanding whether 
proteomic loss of IMM constituents and cardiolipin content was the result of dysfunction 
to the pathway responsible for cardiolipin synthesis. If our hypothesis were to be 
supported, it would suggest a mechanism contributing to mitochondrial dysfunction in 
the diabetic heart. 
 
The biosynthesis of cardiolipin occurs in the IMM and is a multistep process 
(Figure 2.1). To determine whether alterations in the cardiolipin biosynthetic pathway 
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contribute to loss of cardiolipin, mRNA and protein levels for a number of key 
constituents were measured. The results indicated no difference in mRNA levels 
between control and diabetic hearts for any of the enzymes directly responsible for 
cardiolipin biosynthesis; however, a significant decrease in CRLS protein content was 
observed in the diabetic IFM. It is unclear why CRLS protein content was decreased 
specifically in the IFM though the observation may be the result of decreased protein 
import specifically in the diabetic IFM, which has been reported previously (3). 
 
Because CRLS was the only enzyme affected by a type 1 diabetic insult, we 
determined whether the response influenced the activity of the CRLS enzyme. Using 
14C-oleoyl-coenzyme A as an acyl donor, we measured incorporation of 14C to assess 
CRLS activity. One limitation to this method is that remodeling of cardiolipin is not taken 
into account and other methods do not possess this limitation. Nie et al. (24) reported 
that lysophosphatidylglycerol acyltransferase also acts as a CRLS, converting lyso-PG 
to PG; therefore, to ensure the CRLS activity assay was only measuring the 
incorporation of 14C into cardiolipin, we measured the incorporation of 14C into PG. 
Results indicated no change in 14C- PG levels between diabetic and control samples for 
either subpopulation, and a significant decrease in 14C-cardiolipin levels in diabetic IFM 
compared to control, with no change in the SSM. These results instill confidence that 
the methods utilized in our studies are reliable. 
 
Though our data indicated decreased CRLS protein content and activity in the 
diabetic IFM relative to control with no change observed in the SSM, the protein content 
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of CRLS was not different between the SSM and IFM subpopulations; therefore, this 
eliminated the possibility that absolute CRLS protein levels underlie the decreased 
CRLS activity observed in the IFM. Hatch et al. (16) reported no change in PG or 
cardiolipin biosynthesis during a 4 day or 28 day diabetic insult in rats and Taylor et al. 
(30) suggested that neither cardiolipin content nor CRLS activity was altered during 
STZ-induced diabetes. These results were obtained by examining total mitochondria as 
opposed to our current study examining mitochondrial subpopulations, which may 
explain the different results between studies. In either case, the results support the 
importance of examining the two distinct pools of mitochondria.  
 
Previous research has indicated an association between cardiolipin and ETC 
complexes I, III and IV, from which the contact points with cardiolipin have been 
identified (12, 27). Literature has also shown an association between cardiolipin and 
ATP synthase (1, 11). One study demonstrated that cardiolipin is central for the 
assembly of ATP synthase dimers, affecting the organization and ultimately the 
structure of the IMM (1). Other studies have suggested that the interaction between 
cardiolipin and the ATP synthase complex occurs on subunits composing the F0 
complex of the ATP synthase due to its location within the IMM (11). Although an 
association between cardiolipin and ATP synthase has been reported, the direct contact 
points have not been identified. For this reason, we used a novel cardiolipin-coated 
bead assay to separate out the two pools of specific ATP synthase subunits – those 
already bound to native cardiolipin and those available to bind to the cardiolipin-coated 
beads. The ATP synthase subunits predicted to interact with cardiolipin were identified 
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using previous proteomic data performed in our laboratory (3). Western blot analysis 
revealed two direct associations between cardiolipin and ATP synthase. 
 
It is important to note that although the cardiolipin-bead pull-down assay is a 
quick and accessible method to gather cardiolipin-protein interaction data, the assay 
requires a large amount of protein. This is a limitation when measuring associations 
within mitochondrial subpopulations, due to limited yields of mitochondrial subpopulation 
protein content as compared to the analysis of total mitochondria. Nevertheless, we are 
the first to detect direct associations between cardiolipin and two specific ATP synthase 
subunits. 
 
To gain insight into whether cardiolipin association with the identified ATP 
synthase subunits was compromised in diabetic mitochondria, we performed analyses 
in control and diabetic mitochondria. Western blot analysis revealed a lighter band when 
measuring the association between specific ATP synthase subunits and native 
cardiolipin (represented by the native bound lane) in the diabetic IFM compared to 
control. This finding suggests that the association between the native form of cardiolipin 
and the ATP synthase subunits is less in the diabetic IFM compared to control. Western 
blot analysis also revealed a denser band when measuring the association between the 
subunit and cardiolipin-coated beads (represented by the bead bound lane) in the 
diabetic IFM compared to control. The denser band suggests that more ATP synthase 
subunits are not in association with cardiolipin, but are free to bind to the cardiolipin-
coated beads in the diabetic IFM. Taken together, these results indicate that the 
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decrease in interaction between native cardiolipin and ATP synthase could be an 
underlying mechanism causing decreased ATP synthase activity in the diabetic IFM. 
 
A number of studies have utilized cell lines to examine the physiological role of 
cardiolipin. When the structural gene encoding CRLS was disrupted resulting in 
depletion of cardiolipin in the mitochondrial membranes of Saccharomyces cerevisiae 
cells, ATPase activities, cytochrome oxidase activities, membrane potential and protein 
import were all decreased (18). This study concluded that cardiolipin is required for 
maintaining mitochondrial function. Chen et al. (5) identified and characterized the 
cDNA encoding human CRLS. The human CRLS was expressed in COS-7 cells from 
which cardiolipin was not only efficiently synthesized in vitro using CDP-DAG and PG as 
substrates, but was also synthesized at an increased rate. Kiebish et al. (19) 
determined that CRLS overexpression in a STZ-induced diabetic model attenuated 
mitochondrial dysfunction associated with diabetes mellitus. Although these authors did 
not find a difference in total cardiolipin content between diabetic and control hearts, the 
overexpression of CRLS increased cardiac cardiolipin remodeling and lipidomic flux, 
which in turn, increased tetralinoleic cardiolipin. The novel finding of CRLS-mediated 
regulatory control was central in the preservation of mitochondrial function during 
diabetic insult. This study further supports the importance of IMM preservation.  
 
Though our data suggest that changes in essential constituents in the cardiolipin 
biosynthetic pathway (i.e., CRLS) are associated with a decrease in cardiolipin, it is 
important to note that diabetes mellitus is a multifactorial disease that influences a 
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number of processes, specifically in mitochondria.  Increased content of the oxidized 
form of cardiolipin in the diabetic IFM has been reported by our laboratory (Dabkowski 
et al. 2009), thus one must consider that an oxidative stress pathway may also be 
contributing to the results reported in this study. Increased oxidation of cardiolipin would 
likely predispose the phospholipid to loss, influencing mitochondrial functionality (22). 
Future studies in which manipulation of mitochondrial oxidative milieu specifically at the 
IMM may lend insight into the contribution of oxidative stress.  
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CONCLUSION 
In conclusion, our results indicate the importance of preserving the IMM during 
type 1 diabetes mellitus. We show dysregulation of the cardiolipin biosynthetic pathway 
during a diabetic setting, as seen by a decrease in CRLS protein content and activity in 
the diabetic IFM. These studies are the first to demonstrate a direct association 
between cardiolipin and ATP synthase F0-complex subunit b and d in both mitochondrial 
subpopulations. CRLS and IMM conservation represents a potential therapeutic target 
that may be manipulated for treatment against development of cardiomyopathy 
associated with the type 1 diabetic heart.  
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Figure 2.1 Cardiolipin biosynthetic pathway. Schematic diagram illustrating 
cardiolipin biosynthetic pathway. 
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Figure 2.2 
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Figure 2.2 Protein content of cardiolipin biosynthetic pathway constituents. 
Assessment of cardiolipin biosynthetic pathway constituents was performed by Western 
blot using specific antibodies. (A) and (B): representative CDS content from SSM and 
IFM control (n=7) and diabetic (n=8), respectively; (C) and (D): representative PGS 
content from SSM (n=7 for each group) and IFM (n=8 for each group) control and 
diabetic, respectively; (E) and (F): representative CRLS content from SSM and IFM 
control (n=8) and diabetic (n=7), respectively; (G) and (H): representative TAZ content 
from SSM and IFM control (n=7) and diabetic (n=7), respectively. Control for loading 
was confirmed using COX IV probing. Values are expressed as means + SEM; *P< 0.05 
for control vs. diabetic groups. Abbreviations: CDS = cytidine diphosphate diacylglycerol 
synthase; PGS = phosphatidylglycerol synthase; CRLS = cardiolipin synthase; TAZ = 
tafazzin; IFM = interfibrillar mitochondria; SSM = subsarcolemmal mitochondria. 
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Figure 2.3 
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Figure 2.3 Cardiolipin synthase (CRLS) activity. CRLS activity was assessed using a 
14C-acyl donor. (A): CRLS activity measured in SSM diabetic and control samples. (B): 
CRLS activity measured in IFM diabetic samples compared to control samples. (C): PG 
radioactive counts/minute/mg of protein measured in SSM diabetic samples compared 
to control samples. (D): PG radioactive counts/minute/mg of protein measured in IFM 
diabetic samples compared to control samples. Values are expressed as means+ SEM; 
n=8 for each group. *P < 0.05 for control vs. diabetic groups. Abbreviations: CDS = 
cytidine diphosphate diacylglycerol synthase; PG = phosphatidylglycerol; IFM = 
interfibrillar mitochondria; SSM = subsarcolemmal mitochondria. 
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Figure 2.4 
A.                                   SSM B.                                  IFM 
  
 
  
* 
90 
 
Figure 2.4 ATP synthase activity. Spectrophotometric analysis of ATP synthase 
activities in control and diabetic samples. (A): ATP synthase activity from SSM control 
and diabetic groups. (B): ATP synthase activity from IFM control and diabetic groups. 
Values are expressed as means + SEM; n=4 for each group. *P< 0.05 for control vs. 
diabetic groups. Abbreviations: IFM = interfibrillar mitochondria; SSM = subsarcolemmal 
mitochondria. 
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Figure 2.5 
A. ATP5F1 B. ATP5H 
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Figure 2.5 Cardiolipin – ATP synthase association. Mitochondrial protein was 
incubated with cardiolipin-coated beads. Western blots were performed to determine 
associations between cardiolipin and (A): ATP synthase subunit b (ATP5F1); n=3 for 
each group and (B): ATP synthase subunit d (ATPH); n=3 for each group (C): ATP 
synthase alpha (ATP5A); n=2 for each group and (D): ATP synthase beta (ATPB); n=2 
for each group and (E): Glucose regulated protein (GRP75) in the SSM; n=3 for each 
group and (F): Glucose regulated protein (GRP75) in the IFM; n=3 for each group using 
specific antibodies (Representative blots shown). Abbreviations: IFM = interfibrillar 
mitochondria; SSM = subsarcolemmal mitochondria. 
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Figure 2.6 
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Figure 2.6  Native cardiolipin – ATP synthase association. The association between 
cardiolipin and the detected interactions were measured in control and diabetic 
mitochondrial subpopulations. (A): Representation of ATP5F1 protein content in control 
and diabetic SSM and IFM, respectively. The “Bead bound” column represents ATP5F1 
that was eluted off of the cardiolipin-coated beads, whereas the “Native bound” column 
represents ATP5F1 associated with native cardiolipin that was present in the 
supernatant. The “Total” band represents the total ATP5F1 protein content in isolated 
mitochondria. (B): Representation of ATP5H in the same manner as ATP5F1 (Figure 
2.6A). Quantification of the association between native cardiolipin and ATP5F1 in 
control and diabetic hearts in (C): SSM and (E): IFM. Quantification of the association 
between native cardiolipin and ATP5H in control and diabetic hearts in (D): SSM and 
(F): IFM. Values are expressed as means + SEM; n=3 for each group. *P< 0.05 for 
control vs. diabetic groups. Abbreviations: IFM = interfibrillar mitochondria; SSM = 
subsarcolemmal mitochondria. 
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Table 2.1 
mRNA  
Diabetic vs. 
Control 
p-value 
Cardiolipin biosynthesis  
Cytidine diphosphate-diacylglycerol synthase 1  1.18 0.17 
Phosphatidylglycerol synthase 1  0.92 0.47 
Cardiolipin synthase  0.98 0.91 
Tafazzin  0.86 0.24 
Protein import  
Mitochondrial import inner membrane translocase subunit TIM16  0.98 0.89 
Mitochondrial import inner membrane translocase subunit TIM14  0.97 0.98 
Oxidative phosphorylation  
NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial  0.91 0.20 
NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial  1.05 0.60 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 1  0.97 0.84 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2  0.98 0.92 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 3  0.94 0.45 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4  0.95 0.63 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12  0.92 0.62 
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial  1.02 0.88 
Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial  0.62 0.000049 
Cytochrome b-c1 complex subunit 1, mitochondrial  1.06 0.49 
Cytochrome b-c1 complex subunit Rieske, mitochondrial  0.96 0.69 
Cytochrome c1, heme protein, mitochondrial  0.99 0.98 
ATP synthase subunit b, mitochondrial  0.97 0.75 
Miscellaneous  
Prohibitin-2  0.88 0.40 
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Table 2.1. mRNA analysis of inner mitochondrial membrane proteins. mRNA was 
isolated from control and diabetic hearts. The mRNA content levels for inner 
mitochondrial membrane proteins were assessed. Values are expressed as fold change 
in diabetic heart as compared to control heart; n=4 for each group. The bold value 
indicates a p-Value < 0.05 for diabetic vs. control hearts.  
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ABSTRACT 
 
Mitochondrial dysfunction is a central contributor to the development of diabetic 
cardiomyopathy. The examination of mitochondrial function is further complicated by the 
existence of two cardiac mitochondrial subpopulations, subsarcolemmal mitochondria 
(SSM) and interfibrillar (IFM) mitochondria. We have previously reported decreased 
SSM function in type 2 db/db mouse heart. Currently, subpopulation based 
mitochondrial analyses have not been explored in type 2 diabetic human heart. The 
goal of this study was to examine the impact of type 2 diabetic insult on mitochondrial 
function in the human heart. Mitochondrial subpopulations were isolated from atrial 
appendages of non-diabetic and diagnosed type 2 diabetic patients. Glucose-mediated 
and fatty acid-mediated state 3 and state 4 respiration rates were decreased in diabetic 
SSM as compared to non-diabetic SSM (P < 0.05 for both), with no change in IFM. 
Electron transport chain complexes I and IV activities were decreased in diabetic SSM 
compared to non-diabetic SSM (P < 0.05 for both), with a concomitant decrease in 
complex I and IV protein content in diabetic SSM (P < 0.05 for both). The primary factor 
accounting for mitochondrial function was diabetes mellitus, when compared to other 
co-morbidities such as coronary artery disease and hypertension. Using spline models 
to determine correlative risk for mitochondrial dysfunction indicated that diabetic 
patients display the same level of state 3 and electron transport chain complex I 
dysfunction regardless of absolute glycated hemoglobin (HbA1c) and blood glucose 
levels. Overall, the results suggest that independent of other pathologies mitochondrial 
dysfunction is present in the SSM of type 2 diabetic patients and identifies a threshold 
99 
 
where mitochondrial dysfunction is present regardless of absolute HbA1c or blood 
glucose levels.  
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INTRODUCTION 
  
Diabetes mellitus is a condition that is increasingly becoming an epidemic, with 
an estimated 330 million affected worldwide by the year 2030 (10). Of the individuals 
diagnosed with the disease, type 2 diabetes mellitus accounts for approximately 90-
95% of cases (10), and has been attributed to sedentary lifestyle (20). Type 2 diabetes 
mellitus results from insulin resistance caused by an imbalance of the body’s glucose 
homeostasis (20). The body does not properly use the insulin produced in response to 
increased blood glucose levels; therefore, the pancreas eventually loses its ability to 
produce insulin (10). 
   
Cardiovascular complications are the leading cause of morbidity and mortality in 
individuals with diabetes mellitus (17). Mitochondrial dysfunction has been shown to 
contribute to the development of these cardiovascular complications during type 2 
diabetes mellitus (7, 8, 13). In the cardiomyocyte, there are two mitochondrial 
subpopulations that are morphologically, biochemically, and spatially distinct (15, 23). 
The two separate pools of mitochondria respond differently in the face of a 
cardiovascular insult, such as diabetes, aging, and ischemia/reperfusion (13, 14, 21, 
22). The subsarcolemmal mitochondria (SSM) are located just beneath the 
sarcolemma, whereas the interfibrillar mitochondria (IFM) are located in between the 
myofibrils.  
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Previously, examination in a type 2 diabetic db/db mouse model revealed cardiac 
dysfunction (6, 28). When mitochondrial function was assessed, decreased respiration 
rates and oxidative phosphorylation were observed (26). Upon examination of the two 
separate pools of mitochondria, our laboratory observed decreased respiration and 
oxidative phosphorylation, as well as an altered proteomic profile primarily in the 
diabetic SSM, with the IFM being affected to a lesser extent (13). 
 
Though animal studies have provided convincing evidence of differential 
responses by spatially-distinct mitochondrial subpopulations during type 2 diabetic 
insult, studies confirming these effects in a human patient population are limited. 
Skeletal muscle biopsies have been revealed decreased mitochondrial function in 
skeletal muscle of type 2 diabetic patients (19), specifically in the SSM subpopulation 
(25). Fewer studies have examined the human heart due to the invasive procedure 
required to obtain human heart tissue. Anderson et al. reported decreased 
mitochondrial function in type 2 diabetic atria (3, 4). Nevertheless, it is still unclear as to 
how diabetes mellitus affects mitochondrial subpopulations in the diabetic human heart. 
 
The goal of this study was to determine how mitochondrial subpopulations are 
affected in the heart of type 2 diabetic patients compared to non-diabetic patients. Our 
results suggest that type 2 diabetes mellitus negatively impacts the SSM to a greater 
extent than the IFM and that the observed dysfunction may be attributed to decreased 
oxidative phosphorylation machinery. Our data also demonstrate that compounding co-
morbidities, such as coronary artery disease (CAD), hypertension and body mass index 
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(BMI), alone do not influence the observed mitochondrial dysfunction in the type 2 
diabetic SSM.  
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MATERIALS AND METHODS 
 
Human Patient Population 
The West Virginia University Institutional Review Board and Institutional 
Biosafety Committee approved all protocols. Individuals undergoing coronary artery 
bypass graft surgery or cardiac valve replacement at Ruby Memorial Hospital 
consented for the release of their cardiac tissue to West Virginia University School of 
Medicine. Consenting individuals were then characterized as non-diabetic or diabetic 
based upon prior diagnosis of diabetes mellitus. All demographic and clinical data are 
shown in Table 1. 
 
Individual Mitochondrial Subpopulations Isolation 
Right atrial appendages were removed from patients and rinsed in phosphate 
buffered saline (PBS, pH 7.4). Pericardial fat was then trimmed and the heart tissue was 
weighed. The SSM and IFM were isolated as previously described by Palmer et al. (23) 
with modifications by our laboratory (15, 16, 33). Mitochondrial pellets were 
resuspended in KME buffer (100 mM KCl, 50 mM MOPS, and 0.5 mM EDTA) for 
mitochondrial respiration, flow cytometric analyses, and enzymatic activity 
measurements. Protein content was determined by the Bradford method using bovine 
serum albumin as a standard (9). 
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Mitochondrial Size, Internal Complexity and Membrane Potential  
Mitochondrial subpopulation size, internal complexity and mitochondrial 
membrane potential were examined as previously described by our laboratory with 
modifications (13, 15, 33). Briefly, flow cytometric analyses were performed using a 
FACS Calibur equipped with a 15-MW 488-nm argon laser and 633-nm red diode laser 
(Becton Dickinson, San Jose, CA). The ratiometric dye 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazol carbocyanine iodide (JC-1; Molecular Probes, Carlsbad, CA), 
was used to selectively stain and gate for respiring mitochondria. Freshly isolated 
mitochondrial subpopulations were incubated with JC-1 for 15 min at 37°C, and the 
samples were run for 30 seconds. Forward scatter (FSC) and side scatter (SSC) 
detectors were used to examine size (FSC) and complexity (SSC) in isolated 
mitochondrial subpopulations. Changes in membrane potential were recorded as the 
ratio between the color change from green to orange. Measurements were performed 
on freshly isolated mitochondrial subpopulations. All flow cytometric measurements 
were performed in conjunction with the West Virginia University Flow Cytometry Core 
Facility. 
 
Mitochondrial Respiration Rates 
State 3 and state 4 respiration rates were measured in isolated mitochondrial 
subpopulations as previously described (11, 12, 18), with modifications (16). Briefly, 
isolated mitochondrial subpopulations were resuspended in KME buffer. Protein content  
was determined by the Bradford method (9). Fifty micrograms of protein was added to 
respiration buffer (80 mmol/l KCl, 50 mmol/l MOPS, 1 mmol/l EGTA, 5 mmol/l KH2PO4, 
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and 1 mg/ml BSA) and placed into the respiration chamber connected to an oxygen 
probe (OX1LP-1mL Dissolved Oxygen Package, Qubit System, Kingston, ON, Canada). 
Maximal glucose-mediated respiration was initiated by the addition of glutamate (5 mM) 
and malate (5 mM). Maximal fatty acid-mediated respiration was initiated by the addition 
of palmitoylcarnitine (40 µM) and malate (5 mM). Measurements of state 3 (250 mM 
ADP) and state 4 (ADP-limited) respiration were made as previously described (7). 
Values were expressed as nmol of oxygen consumed -min-1-mg protein-1. 
 
Electron Transport Chain (ETC) Complex Activities 
Complex I, complex III, and complex IV activities were measured 
spectrophotometrically as previously described (13, 15, 16, 29). Complex I activity was 
determined by measuring the oxidation of NADH at 340 nm and complex III activity was 
determined by measuring the reduction of cytochrome c at 550 nm in the presence of 
reduced decylubiquinone (50 µM). Complex IV activity was determined by measuring 
the oxidation of cytochrome c at 550 nm. Protein content  was determined by the 
Bradford method (9), and values were expressed as activities (in nmol substrate 
consumed·min-1·mg protein-1). 
 
Electron Transport Chain Complex Protein Expression 
To assess electron transport chain complex I and IV abundance within the non-
diabetic and diabetic human heart, blue native polyacrylamide gel electrophoresis (BN-
PAGE) was performed according to the manufacturer's protocol (Invitrogen, Carlsbad, 
CA). Briefly, 20 μg of isolated mitochondria were solubilized with 1% digitonin for 15 min 
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on ice. After addition of 1.25 μl of Coomassie G-250, samples were run on 4–16% 
NativePAGE gels at 120 V for 90 min at room temperature. Gels were transferred to 
PDVF membranes and subsequently probed with an anti-ND-1 goat antibody (Product 
No. 20493, Santa Cruz, CA) and an anti-cytochrome c oxidase rabbit antibody (product 
No. ab16056, Abcam, Cambridge, MA). The secondary antibodies used were a donkey 
anti-goat IgG horseradish peroxidase conjugate (Product No. 2020, Santa Cruz, CA)  
and a goat anti-rabbit IgG horseradish peroxidase conjugate (product No. 10004301, 
Cayman Chemical Company, Ann Arbor, MI).  Detection of signal was performed 
according to the Pierce ECL Western Blotting Substrate detection system 
manufacturer’s directions (Thermo Fisher Scientific, Rockford, IL). Quantification of 
chemiluminescent signals were assessed using a G:Box Bioimaging System (Syngene, 
Frederick, MD), and the data captured using GeneSnap software (Syngene, Frederick, 
MD). Densitometry was measured using Image J Software (National Institutes of Health, 
Bethesda, MD). 
 
Statistics  
Means and SEM were calculated for all data sets. Data shown in Table 1 and in 
all subsequent figures were analyzed with a Student’s t-test. P < 0.05 was considered 
statistically significant. Logistic regression was performed to determine if any co-
morbities were associated with being diabetic. For patients with HbA1c measurements, 
the relationship between HbA1c and the outcomes were assessed using a linear spline 
model with a break-point at HbA1c equal to 6.5%. The World Health Organization states 
that a patient is considered diabetic if HbA1c level is equal to or greater than 6.5% (32). 
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This allowed for different linear relationships for those with HbA1c less than 6.5% and 
those above 6.5%. The relationship between blood glucose levels and the outcomes 
were also assessed using a linear spline model with a break-point at a blood glucose 
level equal to 200 mg/dL, which is the level used  by the American Diabetes Association 
to diagnose a patient as diabetic (1). 
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RESULTS 
 
Patient Characteristics Table 
As seen in Table 3.1, eighty one patients were separated into two groups, non-
diabetics and diabetics, based on prior diagnosis. The ages and sexes between the two 
groups were similarly distributed and all the patients were Caucasian. The diabetic 
patients had significantly higher BMI levels, higher HbA1c levels, as well as higher 
blood glucose levels (P < 0.05 for all three). Greater than 80% of both populations had 
hypertension and CAD. Medications that the patients were receiving were also noted. 
Diabetic patients were actively receiving medications, such as Metformin or insulin, as 
treatment for diabetes mellitus. The majority of patients regardless of diabetic status 
were receiving beta-blockers, angiotensin-converting-enzyme (ACE) inhibitors and/or 3-
hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins). 
 
Mitochondrial Morphology and Membrane Potential 
Literature has suggested that mitochondrial dysfunction contributes to 
mitochondrial morphological alterations (13, 19, 25). Isolated mitochondria were 
analyzed by flow cytometry using a dye that only migrates into respiring mitochondria 
that contain a membrane potential. The mitochondria that were respiring were gated, 
which allowed only those mitochondria, and not debris, to be measured. Forward and 
side scatter histograms revealed two different populations, as determined by size and 
complexity (Figure 3.1A and 3.1B, respectively). No differences in mitochondrial size or 
internal complexity were observed between diabetic and non-diabetic patients for either 
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subpopulation (Figures 3.1C and 3.1D). Although we did not see an alteration in 
mitochondrial size and internal complexity due to type 2 diabetes mellitus, we observed 
that the SSM were larger in size and had a greater internal complexity compared to IFM 
(P < 0.05; Figure 3.1C and 3.1D, respectively), which is supported by previous findings 
in mouse models (13, 15, 33). 
 
Using a mouse model, our laboratory has previously reported higher membrane 
potential in the IFM compared to the SSM measured by flow cytometry (5, 15). In the 
human heart, IFM exhibited a greater membrane potential compared to SSM but no 
change was observed between non-diabetic and diabetic patients (P < 0.05; Figure 
3.1E). 
  
Mitochondrial Respiration 
 Mitochondrial respiration rates were measured in isolated mitochondrial 
subpopulations from non-diabetic and diabetic patients. When using glutamate and 
malate as substrates to measure maximal glucose-mediated respiration, diabetic SSM 
displayed significantly decreased state 3 and state 4 respiration rates as compared to 
the non-diabetic SSM (P < 0.05; Figure 3.2A), with no differences observed in the IFM 
(Figure 3.2B).  
 
Glycolysis is impaired during type 2 diabetes mellitus; therefore, the heart must 
rely primarily on fatty acid oxidation as an energy source (2). When using 
palmitoylcarnitine and malate as substrates to measure maximal fatty-acid respiration, 
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both state 3 and state 4 respiration rates in the diabetic SSM were significantly 
decreased (P < 0.05; Figure 3.2C), with no change for either state in the IFM (Figure 
3.2D).  
 
To determine whether the degree of hyperglycemia and HbA1c level was 
predictive of the mitochondrial dysfunction we observed in diabetic patients, we 
generated spline models to determine correlative risk. In Figures 3.3A and 3.3B, state 3 
respiration rates were plotted against HbA1c levels, whereas in Figures 3.3C and 3.3D, 
state 3 respiration rates were plotted against blood glucose levels. In each model, we 
selected a break-point (dashed line) that represented the value at which a diagnosis of 
diabetes mellitus is performed in a clinical setting. For HbA1c a value of 6.5% was 
selected while for blood glucose, a value of 200 mg/dL was selected. Both of these 
values are used to make a diabetic diagnosis (1, 32). In Figures 3.3A and 3.3C, non-
diabetic patients (left of the dashed line) displayed linear correlations suggestive of 
decreased state 3 respiration rates with increasing HbA1c or blood glucose level. In 
contrast, diabetic patients (right of the dashed line), displayed linear correlations 
indicating lower state 3 respiration rates which were similar regardless of increasing 
HbA1c or blood glucose level (Figures 3.3A and 3.3C). Contrary to SSM, The similar 
analyses in IFM indicated linear slopes that were more similar between diabetic and 
non-diabetic patients (Figures 3.3B and 3.3D). 
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Electron Transport Chain Complex Activities 
 Mitochondrial function was further examined by measuring ETC complex 
activities. As seen in Figure 3.4, ETC complexes I and IV activities were significantly 
decreased in the SSM of type 2 diabetic patients relative to non-diabetics (P < 0.05, 
Figure 3.4A). ETC complex III did not differ in the SSM of non-diabetic and diabetic 
patients. ETC complexes I, III and IV activities were not altered in diabetic IFM as 
compared to non-diabetic IFM (Figure 3.4B).  
 
 As above, we determined whether the degree of hyperglycemia and HbA1c level 
was predictive of the ETC complex I functional decrement observed in diabetic patients, 
using a spline model. In Figures 3.5A and 3.5B, ETC complex I activities were plotted 
against HbA1c levels, whereas in Figures 3.5C and 3.5D, ETC complex I activities were 
plotted against blood glucose levels. In Figures 3.5A and 3.5C, non-diabetic patients 
(left of the dashed line) displayed linear correlations suggestive of decreased ETC 
complex I activity with increasing HbA1c or blood glucose level. In contrast, diabetic 
patients (right of the dashed line), displayed linear correlations indicating lower ETC 
complex I activity which was similar regardless of increasing HbA1c or blood glucose 
level (Figures 3.5A and 3.5C). As above, similar analyses in IFM indicated linear slopes 
that were more similar between diabetic and non-diabetic patients (Figures 3.5B and 
3.5D). 
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Examination of Electron Transport Chain Complex Protein Expression  
To determine whether loss of ETC complexes was associated with decreased 
enzymatic activity, we assessed the protein content of ETC complexes by BN-PAGE. 
Both ETC complex I and complex IV were significantly decreased in the diabetic SSM 
(P < 0.05, Figures 3.6A and 3.7A, respectively). In contrast, no differences in protein 
content for ETC complexes I or complex IV in the diabetic IFM compared to non-
diabetic IFM (Figures 3.6B and 3.7B, respectively). These results suggest a possible 
mechanism underlying the observed decrease in mitochondrial function of the diabetic 
SSM compared to the non-diabetic SSM.  
 
Presence of Type 2 Diabetes Mellitus, Coronary Artery Disease and Hypertension 
 Because many of the patients studied possessed other comorbidities, we were 
not able to separate the diabetic patients from the non-diabetic patients without 
including those with both CAD and hypertension. Nevertheless, we attempted to 
determine whether the presence of a specific comorbidity was responsible for the 
observed effects on mitochondrial function. Patients were grouped into three categories: 
(1) non-diabetic and diabetic patients with both CAD and hypertension; (2) non-CAD 
and CAD patients without diabetes mellitus; and (3) non-hypertensive and hypertensive 
patients without diabetes mellitus. These groups were chosen because they enabled us 
to isolate out the individual comorbidities without the presence of diabetes mellitus 
(groups 2 and 3) and enable comparison with diabetic and non-diabetic patients who 
possessed both comorbidities (group 1). Table 3.2 displays the mitochondrial functional 
analyses of non-diabetic and diabetic patients who all have CAD and hypertension and 
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the data shows a decrease in both mitochondrial respiration and ETC complex I and IV 
activity of diabetic patients who have CAD and hypertension. Table 3.3 represents 
mitochondrial functional analyses of patients who had or did not have CAD, of which 
none of the patients were hypertensive or diabetic and results indicated no observed 
mitochondrial dysfunction in the patients who possessed CAD. Table 3.4 illustrates the 
mitochondrial functional analyses of patients who were or were not hypertensive, of 
which none had CAD or were diabetic and similarly, data demonstrated that the 
mitochondrial function of these hypertensive patients. These results suggest that the 
mitochondrial dysfunction observed in type 2 diabetic patients who have both CAD and 
hypertension is not due to either CAD or hypertension independently. 
 
The Influence of Body Mass Index (BMI) on Type 2 Diabetes Mellitus  
 We sought to determine the influence of BMI on SSM mitochondrial function 
during type 2 diabetes mellitus using a similar spline approach. The linear spline models 
in Figures 3.8A and 3.8B include a break-point at an HbA1c level equal to 6.5% (dashed 
line). Based on the World Health Organization, patients whose BMI is less than 30 
kg/m2 are considered non-obese, whereas patients whose BMI is greater than 30 kg/m2 
are considered obese (31). Patients with a BMI < 30 kg/m2 are indicated in white while 
those patients with a BMI > 30 kg/m2 are indicated in black (Figures 3.8A and 3.8B). 
After categorizing the patients as non-obese or obese, we were able to visualize the 
impact of obesity on these two measurements of mitochondrial function (Figure 3.8). If 
obesity were impacting mitochondrial function to a great extent, we would expect to see 
the obese patients clustered at the bottom of the spline model, indicating a lower 
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mitochondrial function compared to the non-obese patients. Interestingly, we observed 
an even displacement of the obese patients throughout the patients’ data, indicating that 
obesity does not independently impact mitochondrial function, specifically SSM state 3 
respiration and SSM ETC complex I activity as measured by HbA1c levels. Our results 
indicated that SSM state 3 respiration (Figure 3.8A) and SSM ETC complex I activity 
(Figure 3.8B) are not correlated with a patient’s BMI, regardless of diabetic status. 
These findings suggest that the BMI level of an individual is not an effective predictor of 
type 2 diabetic status nor mitochondrial dysfunction. 
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DISCUSSION 
 
Mitochondrial dysfunction contributes to cardiovascular complications that are 
associated with type 2 diabetes mellitus (13, 19, 24, 25). The existence of two 
mitochondrial subpopulations present in the cardiomyocyte further complicates 
mitochondrial functional analyses. Our laboratory and others have reported that these 
two separate pools of mitochondria are affected differently by pathologies, such as 
diabetes mellitus in rodent models (13, 14, 21, 22). Limited research has used a human 
heart model to examine mitochondrial function (30) and the effects of diabetes mellitus 
(3, 4). The goal of this translational study was to determine how type 2 diabetes mellitus 
affects individual mitochondrial subpopulations in human patients. Our results suggest 
that mitochondrial dysfunction is present in the heart of human type 2 diabetic patients, 
with the SSM being affected to a greater extent than the IFM, as demonstrated by 
decreased glucose- and fatty acid–mediated respiration, ETC complex I and IV activities 
and complex expression. 
 
With our large data set, we were able to analyze relationships between non-
diabetics and diabetics by examining state 3 mitochondrial respiration and ETC complex 
I activities. By utilizing linear regression spline models for state 3 mitochondrial 
respiration as well as ETC complex I activity and separating non-diabetic and diabetic 
patients by HbA1c levels, a decreasing slope for non-diabetic patients suggested that 
as HbA1c level increases, SSM state 3 respiration and ETC complex I activity 
decreases. Once an HbA1c level of 6.5% is reached, the slope of the linear regression 
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remains somewhat flat despite further increases in HbA1c levels. These findings 
indicate that mitochondrial dysfunction is already present in diabetics with HbA1c levels 
in the modestly elevated range and that as HbA1c levels increase the extent of 
mitochondrial dysfunction remains the same. A similar phenomenon is apparent when 
analyzing SSM state 3 respiration and SSM ETC complex I activity and applying a 
spline model which utilizes a blood glucose level of 200 mg/dL. Taken together these 
findings indicate that mitochondrial dysfunction in the SSM of type 2 diabetic patients is 
present despite the degree of control over key indices that are predictive of patient 
morbidity, such as HbA1c and blood glucose levels. Further, these findings may 
suggest that the presence of the diabetic phenotype independent of the stage or timing 
of the disease is associated with dysfunctional profiles to cardiac mitochondria.  
 
When analyzing the spline models of state 3 respiration and ETC complex 
activity I measured by blood glucose levels, similar relationships are observed as 
compared to examining these mitochondrial functional parameters measured by HbA1c 
levels. In regards to SSM state 3 respiration, the linear regression slope before a blood 
glucose level of 200 mg/dL is noticeably decreasing, with no visible slope for the 
diabetic patients whose blood glucose levels are higher than 200 mg/dL. By comparing 
the two relationships of SSM state 3 mitochondrial respiration between non-diabetic and 
diabetic patients, we were able to determine that SSM state 3 respiration decreased 
with increasing blood glucose levels until a blood glucose level of 200 mg/dL is reached, 
from which no correlation between mitochondrial dysfunction and increasing blood 
glucose levels existed. The spline model of SSM ETC complex activity I measured by 
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blood glucose levels also revealed a similar phenomenon; however, the linear 
regression slope was not as dramatic as with SSM state 3 respiration. With that being 
said, SSM ETC complex I activity decreased with increasing blood glucose levels until a 
blood glucose level of 200 mg/dL was reached. Past this threshold, SSM ETC complex I 
activity dysfunction remained constant, regardless of increasing blood glucose levels. 
 
In contrast to our current study, Rosca et al. reported increased ETC complex I 
and complex III expression levels in the SSM, with no change in ETC complex IV in a 
canine coronary heart failure model as measured by BN-PAGE (27). It is unclear why 
the results from our study differed by may be due in part to differences in the 
pathologies, heart failure vs. diabetes mellitus, as well as the examination of canine and 
human models. Anderson et al (4) reported no change in ETC complexes I-V 
expression in diabetic patients when compared to non-diabetics. This difference may be 
due to the experimental procedures employed. Anderson et al. examined polypeptides 
from denatured proteins as opposed to the protein expression of the individual complex 
as a whole unit, which was the case in our study. This difference could also be 
explained by the examination of homogenate versus mitochondrial subpopulations used 
in the current study.  
 
Examining mitochondrial function in the human heart does not come without 
critical limitations. First, the biopsies are collecting come from individuals undergoing 
cardiac procedures, which may impart negative effects on the heart. Despite this 
complication, we feel that the non-diabetic group of patients is the appropriate group to 
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compare with the diabetic patients because the clinical variables and medications that 
may influence the results are no longer taken into consideration due to the fact that the 
both groups have similar clinical variables, such as CAD, hypertension, and medications 
(Table 3.1).  
 
The presence of other clinical co-morbidities has been a factor in the examination 
of the human heart because most of the patients who are undergoing cardiac 
procedures are diagnosed with a multitude of compounding diseases, such as CAD, 
type 2 diabetes mellitus and hypertension. Although the patients that were diagnosed 
with these illnesses were similarly distributed in both groups (Table 3.1), it is unclear as 
to which disease was affecting the mitochondrial functional outcomes. In this study, we 
were able to determine that CAD, hypertension nor BMI alone were the prominent 
contributing factor to the observed mitochondrial dysfunction (Tables 3.3 and 3.4, and 
Figure 3.8, respectively) in patients with type 2 diabetes mellitus. Our data is in 
agreement with Anderson et al. (4) and indicates that type 2 diabetes mellitus, in the 
presence of CAD and hypertension, is part of a multifaceted interaction that all together 
contributes to mitochondrial dysfunction (Table 3.2). Although we had a large patient 
number, we were unable to separate the effects of type 2 diabetes mellitus alone on 
mitochondrial functionality.  
 
In conclusion, we are the first to demonstrate mitochondrial subpopulation-
specific dysfunction in the human heart of type 2 diabetic patients, with the SSM being 
impacted to a greater extent than the IFM. With the use of linear spline models, we were 
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able to illustrate that once a threshold is reached, either with HbA1c or blood glucose 
levels, mitochondrial dysfunction is no longer correlated with decreasing levels, 
highlighting the importance of preserving mitochondrial function regardless of the stage 
of type 2 diabetic onset. 
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Figure 3.1 
 
A.               SSM Control B.                 IFM Control 
 
 
 
C.                  Mitochondrial Size 
 
D.         Internal Complexity 
  
 
E.  Mitochondrial Membrane Potential 
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Figure 3.1 Mitochondrial characteristics. Cardiac mitochondrial subpopulations were 
isolated and incubated with JC-1 dye. Forward scatter and side scatter were used to 
analyze the isolated mitochondria as seen by a (A) representative histogram of non-
diabetic SSM; and a (B) representative histogram of non-diabetic IFM. Mitochondrial 
size (C) and internal complexity (D) was quantified for each mitochondrial 
subpopulation. By calculating the ratio of green to orange fluorescence, membrane 
potential (E) was quantified for non-diabetic and diabetic SSM and IFM. Closed bars 
represent non-diabetic patients and open bars represent diabetic patients. *P < 0.05 
SSM non-diabetic vs. IFM non-diabetic; N = 28 non-diabetics and 23 diabetics. 
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Figure 3.2 
A.                    SSM Respiration  B.                     IFM Respiration  
  
 
C.                     SSM Respiration  
 
D.                     IFM Respiration  
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Figure 3.2 Mitochondrial subpopulation respiration rates. Cardiac mitochondrial 
subpopulations were isolated and respiration rates were measured using different 
substrates. Glutamate and malate were used as substrates to measure the amount of 
oxygen consumed (State 3 and State 4) for (A) non-diabetic and diabetic SSM and (B) 
non-diabetic and diabetic IFM (N = 28 non-diabetics and 23 diabetics). 
Palmitoylcarnitine and malate were used as substrates to measure the amount of 
oxygen consumed (State 3 and State 4) for (C) non-diabetic and diabetic SSM and (D) 
non-diabetic and diabetic IFM (N = 17 non-diabetics and 10 diabetics). Values are mean 
+ SEM. Units are nmoles O2 consumed/min/mg of protein. Closed bars represent non-
diabetic patients and open bars represent diabetic patients. *P < 0.05 State 3 SSM non-
diabetic vs. State 3 SSM diabetic. †P < 0.05 State 4 SSM non-diabetic vs. State 4 SSM 
diabetic. 
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Figure 3.3 
A.                         SSM State 3 Respiration measured by HbA1c levels 
 
 
B.                           IFM State 3 Respiration measured by HbA1c levels 
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C.                    SSM State 3 Respiration measured by blood glucose levels  
 
 
D.                    IFM State 3 Respiration measured by blood glucose levels  
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Figure 3.3 Linear spline illustrations for mitochondrial respiration. Linear spline 
models for HbA1c and mitochondrial respiration, specifically state 3, were performed 
with a break-point at an HbA1c level equal to 6.5% (dashed line). The linear relationship 
before and after the break-point are plotted for SSM (A) and IFM (B) with dots 
representing each patient with an observed HbA1c level. A linear spline model for blood 
glucose and state 3 mitochondrial respiration was performed with a break-point at a 
blood glucose level equal to 200 mg/dL (dashed line). The linear relationship before and 
after the break-point are plotted for SSM (C) and IFM (D) with dots representing each 
patient with an observed blood glucose level. Units are nmoles O2 consumed/min/mg of 
protein. 
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Figure 3.4  
A.                                 SSM    
 
 
 
B.                                  IFM 
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Figure 3.4 Electron transport chain activities in mitochondrial subpopulations. 
Cardiac mitochondrial subpopulations were isolated and ETC complex I, III, and IV 
activities were measured. ETC complexes I, III, and IV in the non-diabetic and diabetic 
SSM (A) and IFM (B). Values are mean + SEM. Units are activity/min/mg of protein. 
Closed bars represent non-diabetic patients and open bars represent diabetic patients. 
*P < 0.05 SSM non-diabetic vs. SSM diabetic; N = 47 non-diabetics and 34 diabetics. 
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Figure 3.5 
A.                       SSM ETC Complex I Activity measured by HbA1c levels 
 
 
B.                         IFM ETC Complex I Activity measured by HbA1c levels 
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C.                 SSM ETC Complex I Activity measured by blood glucose levels  
 
 
D.                 IFM ETC Complex I Activity measured by blood glucose levels  
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Figure 3.5 Linear spline illustrations for electron transport chain complex I 
activity. Linear spline models for HbA1c and ETC complex I activity, were performed 
with a break-point at an HbA1c level equal to 6.5% (dashed line). The linear relationship 
before and after the break-point are plotted for SSM (A) and IFM (B) with dots 
representing each patient with an observed HbA1c level. A linear spline model for blood 
glucose and ETC complex I activity was performed with a break-point at blood glucose 
level equal to 200 mg/dL (dashed line). The linear relationship before and after the 
break-point are plotted for SSM (C) IFM (D) with dots representing each patient with an 
observed blood glucose level. Units are activity/min/mg of protein. 
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Figure 3.6 
A.        SSM Complex I Blue Native B.                    SSM: Complex I 
 
 
 
C.        IFM Complex I Blue Native 
 
D.                    IFM: Complex I 
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Figure 3.6 Electron transport chain complex I expression. Cardiac mitochondrial 
subpopulations were isolated and subjected to BN-PAGE to measure complex I protein 
content. A component of ETC complex I was used to measure the protein content of 
complex I.  The BN-PAGE blots are illustrated in the non-diabetic and diabetic SSM (A) 
and IFM (C). The optical density was calculated in non-diabetic and diabetic SSM (B) 
and IFM (D). Values are mean + SEM. Closed bars represent non-diabetic patients and 
open bars represent diabetic patients. *P < 0.05 SSM non-diabetic vs. SSM diabetic; N 
= 4 non-diabetics and 4 diabetics. 
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Figure 3.7 
A.          SSM Complex IV Blue Native B.                       SSM: Complex IV 
 
 
 
 
C.         IFM Complex IV Blue Native 
 
D.                        IFM: Complex IV 
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Figure 3.7 Electron transport chain complex IV expression. Cardiac mitochondrial 
subpopulations were isolated and subjected to BN-PAGE to measure complex I and 
complex IV protein content. A component of ETC complex IV was used to measure the 
protein content of complex IV. The BN-PAGE blots are illustrated in the non-diabetic 
and diabetic SSM (A) and IFM (C). The optical density was calculated in non-diabetic 
and diabetic SSM (B) and IFM (D). Values are mean + SEM. Closed bars represent 
non-diabetic patients and open bars represent diabetic patients. *P < 0.05 SSM non-
diabetic vs. SSM diabetic; N = 4 non-diabetics and 4 diabetics. 
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Figure 3.8 
A.           
  
 
B.          
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Figure 3.8 Linear spline illustration for state 3 mitochondrial respiration and ETC 
complex I activity. Linear spline models for HbA1c and SSM state 3 mitochondrial 
respiration and SSM ETC complex I activity, respectively, with a break-point at an 
HbA1c levelg equal to 6.5% (dashed line). (A) Same linear spline model as Figure 3.3A 
and (B) is the same graph as Figure 3.5A, with dots representing each patient with an 
observed HbA1c level. Open dots represent patients whose BMI is less than 30 kg/m2, 
whereas closed dots represent patients whose BMI is greater than 30 kg/m2. Units are 
nmoles O2 consumed/min/mg of protein for mitochondrial respiration and activity/min/mg 
of protein for ETC complex I activity. 
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Table 3.1  
  
Non-diabetic Diabetic 
Demographics Age (years) 60.0 + 1.9 61.2 + 1.8 
 
Sex (M/F) 38/9 22/12 
 
Race Caucasian Caucasian 
Characteristics BMI 29.8 + 0.8 32.8 + 1.1* 
 
HbA1c  (n=37,33) 5.5 + 0.1 8.5 + 0.4* 
 
Avg. BG (n=37,33) 111.8 + 2.4 199.2 + 12.2* 
 
EF 52.8 + 2.1 49.2 + 2.7 
 
Hypertension (n=46,34) 78.3% 85.3% 
 
CAD (n=47,34) 83.0% 91.2% 
Medications Insulin 0/47 12/34 
 
Metformin 0/47 13/34 
 
Sulfonylureas 0/47 6/34 
 
β-blockers 28/47 26/34 
 
ACE inhibitors 15/47 17/34 
 
Statins 27/47 20/34 
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Table 3.1 Patient Demographics and Characteristics. * P < 0.05 Diabetic vs. Non-
diabetic group. 
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Table 3.2  
SSM  State 3 State 4 Complex I Complex III Complex IV 
Non-
diabetic  
65.8 ± 8.4 4.1 ± 0.9 42.9 ± 3.6 24.6 ± 4.9 16.8 ± 2.1 
Diabetic  39.4 ± 6.0* 1.8 ± 0.3* 30.1 ± 2.7* 24.58 ± 4.6 11.0 ± 1.3* 
IFM       
Non-
diabetic  
35.6 ± 5.5 3.4 ± 1.0 54.6 ± 8.5 51.8 ± 11.5 33.3 ± 6.5 
Diabetic  37.4 ± 3.9 2.3 ± 0.6 48.9 ± 5.2 50.6 ± 10.7 24.1 ± 4.8 
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Table 3.2 Non-diabetic and Diabetic Patients with Both Coronary Artery Diseases 
and Hypertension. All patients have both coronary artery disease and hypertension. 
Diabetes mellitus is the only variable in this data set. Values are mean + SEM. Units for 
State 3 and State 4 are nmoles of oxygen consumed/min/mg of protein (N = 21 Non-
diabetics and 20 Diabetic patients). Units from complex activities are activity/min/mg of 
protein (N = 34 Non-diabetics and 27 Diabetic patients).*P<0.05 Diabetic vs. non-
diabetic group. 
  
148 
 
Table 3.3 
SSM  State 3 State 4 Complex I Complex III Complex IV 
Non-
CAD  
82.5 ± 10.7 4.0 ± 0.8 41.8 ± 3.3 23.0 ± 4.4 16.3 ± 1.9 
CAD  84.8 ± 27.6 4.5 ± 0.9 47.2 ± 10.1 21.8 ± 7.8 20.7 ± 3.3 
IFM       
Non-
CAD  
41.8 ± 6.0 3.3 ± 0.8 53.6 ± 7.5 50.3 ± 10.1 32.2 ± 5.7 
CAD  24.7 ± 6.5 3.6 ± 0.9 53.9 ± 10.8 18.4 ± 3.1 37.0 ± 9.5 
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Table 3.3 Non-Coronary Artery Diseases (CAD) and CAD Patients without 
Diabetes Mellitus. None of the patients have diabetes mellitus or hypertension. 
Coronary artery disease is the only variable in this data set. Values are mean + SEM. 
Units for State 3 and State 4 are nmoles of oxygen consumed/min/mg of protein (N = 28 
Non-CAD and 4 CAD patients). Units from complex activities are activity/min/mg of 
protein (N = 42 Non-CAD and 8 CAD patients). 
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Table 3.4 
SSM  State 3 State 4 Complex I Complex III Complex IV 
Non-HT  74 ± 10.8 4.1 ± 0.9 42.8 ± 3.6 24.5 ± 4.7 17.4 ± 2.1 
HT  110.5 ± 20.4 3.8 ± 0.8 42.5 ± 7.2 17.1 ± 5.4 16.0 ± 2.7 
IFM       
Non-HT  34.7 ± 5.4 3.3 ± 0.9 54.7 ± 8.2 50.6 ± 11.2 34.2 ± 6.4 
HT 54.6 ± 13.6 3.3 ± 0.7 50.1 ± 7.3 29.1 ± 7.3 29.0 ± 6.4 
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Table 3.4 Non-Hypertensive (HT) and Hypertensive Patients without Diabetes 
Mellitus. None of the patients have diabetes mellitus or coronary artery disease. 
Hypertension is the only variable in this data set. Values are mean + SEM. Units for 
State 3 and State 4 are nmoles of oxygen consumed/min/mg of protein (N = 25 Non-
hypertensive (Non-HT) and 7 Hypertensive (HT)). Units from complex activities are 
activity/min/mg of protein (N = 40 Non-hypertensive and 10 Hypertensive patients). 
 
  
Chapter 4: 
General Discussion 
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GENERAL DISCUSSION  
 
 The overall objective of this dissertation was to evaluate the impact of both type 
1 and type 2 diabetes mellitus on the IMM. Specifically, we wanted (1) to determine how 
the cardiolipin biosynthesis pathway and cardiolipin-protein interactions were impacted 
by type 1 diabetes mellitus; (2) to determine the therapeutic value of mitochondrial 
Grp75 overexpression on mitochondrial protein import during a type 1 diabetic insult; 
and (3) to examine how mitochondrial subpopulations in the human heart were affected 
by type 2 diabetes mellitus. The long term goal was to understand the importance of 
IMM preservation during diabetes mellitus and to translate rodent mitochondrial 
dysfunction that occurs during diabetic cardiomyopathy to the human diabetic heart. 
The central hypothesis of this dissertation was that the mitochondrion is negatively 
impacted by diabetes mellitus, leading to deleterious effects to the IMM and 
compromising the proteins associated with cardiolipin and protein import, which will 
translate to the diabetic human heart. The rationale for the research conducted for this 
dissertation is based on the importance of preserving the IMM structure and processes 
within to alleviate mitochondrial dysfunction associated with the diabetic heart, as well 
as understanding the effect of diabetes mellitus on human cardiac mitochondrial 
subpopulations. 
  
Cardiovascular complications, such as diabetic cardiomyopathy, are the leading 
cause of morbidity and mortality in patients with diabetes mellitus (13, 15, 25). Multiple 
studies have linked mitochondrial dysfunction with diabetic cardiomyopathy (3, 9, 10, 
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23, 30, 31). Mitochondrial studies are complex in the fact that two distinct mitochondrial 
subpopulations reside in the heart (Figure 1.1). These two spatially distinct pools of 
mitochondria respond differently to pathological insults, such as diabetes mellitus (7-9, 
18, 20, 24). We have previously reported mitochondrial dysfunction in the type 1 
diabetic mouse heart, specifically in IFM, as evidenced by decreased mitochondrial 
respiration, ETC complexes I, III, IV, and V activities, as well as protein import (3, 9). 
Along with increased ROS production, lipid peroxidation and nitrotyrosine residues were 
significantly increased (9). Our laboratory has also reported detriments to the IMM and 
subsequent mitochondrial dysfunction, specifically in SSM of a type 2 db/db mouse 
model (8, 24), as evidenced by decreased mitochondrial respiration and decreased 
Grp75 protein content. We were the first to evaluate the impact of type 2 diabetes 
mellitus on mitochondrial subpopulations in human atrial tissue from which the results 
previously reported from the db/db mouse heart translated into the type 2 diabetic 
human model, suggesting that mitochondria function from type 2 diabetic human heart 
displays similar mitochondrial dysfunctional profiles with SSM primarily impacted.  
 
Literature suggests that ROS production is the underlying mechanism 
contributing to the mitochondrial dysfunction associated with diabetes mellitus (6, 14). 
The main source of ROS production is the IMM, making this membrane more 
susceptible to oxidative damage. The IMM is composed of a specific lipid environment 
that houses many of the critical mitochondrial processes that are required for 
mitochondria to function properly (Figure 1.2), such as oxidative phosphorylation and 
protein import machinery. Our laboratory has reported proteomic alterations in the IFM 
during a type 1 diabetic insult and in the SSM during a type 2 diabetic insult (3, 8). 
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Figure 4.1A represents the mitochondrial proteome and the abundance of proteins 
present in each membrane of the mitochondrion. Of the proteins altered during a type 1 
diabetic insult, 51% reside in the IMM (Figure 4.1B). Similarly, of the proteins altered 
during a type 2 diabetic insult, 50% reside in the IMM (Figure 4.1C). By comparing the 
pie charts between the different disease states versus control, one can recognize that 
the IMM is most affected by diabetes mellitus (17).  
 
         A.     Mitochondrial Proteome 
 
 
Mitochondrial compartments: 
 OMM = outer mitochondrial membrane 
 IMM = inner mitochondrial membrane 
 IMS = inner mitochondrial space  
 Matrix 
B.     Type 1 Diabetic IFM C.     Type 2 Diabetic SSM 
  
Figure 4.1. Mitochondrial proteome during different diabetic states. (A) Pie chart 
representing the percentage of proteins present in each membrane of mitochondria in a 
control setting. (B) Pie chart representing the percentage of proteins altered during a 
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type 1 diabetic insult in the IFM. (C) Pie chart representing the percentage of proteins 
altered during a type 2 diabetic insult in the SSM (17). 
 
Cardiolipin is a key phospholipid that is required for the stability of the IMM (27), 
as well as for proper functioning of many IMM proteins (Figure 1.3), including the 
oxidative phosphorylation machinery, cytochrome c attachment and protein import 
machinery (12, 19, 22, 28, 32). Tetralinoleic cardiolipin is the most dominant form of 
cardiolipin in the heart; however, other forms exist in different tissues and during 
different pathologies (1, 27). Our laboratory and others reported a decrease in total 
cardiolipin and tetralinoleic cardiolipin during a type 1 diabetic insult (Chapter 2) (16), 
specifically in IFM (9). Preliminary data generated from type 2 diabetic human atrial 
tissue utilizing high performance thin layer chromatography also revealed lower total 
cardiolipin content in the diabetic SSM (not significant) (Figure 6.5).  
 
Although both type 1 and type 2 diabetes mellitus are a consequence of a 
hyperglycemic environment, the manifestation and phenotypes between the diseases 
differ. For example, chapters 2 and 6 reported decreased cardiolipin content in both IFM 
(type 1) and SSM (type 2), which could be caused by different pathways depending on 
the type of diabetes mellitus. During type 2 diabetes mellitus, fatty acid oxidation and 
oxidative stress precede the hyperglycemic environment (5), from which circulating fatty 
acids, as well as triglyceride levels, are increased (33). Because SSM are located just 
beneath the sarcolemma, this population is affected to a greater extent than IFM during 
type 2 diabetes mellitus. Supporting this statement, proteins involved in fatty acid 
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oxidation were reported to be increased to a greater extent in type 2 diabetic SSM, 
compared to IFM, resulting in an enhanced lipid environment (8). Literature has also 
stated that individuals with type 2 diabetes mellitus tend to be more obese and were 
subjected to myocardial lipotoxicity (4); therefore, cardiolipin content could be 
decreased in type 2 diabetic SSM due to the enhanced oxidative environment and 
increased lipotoxicity.  
 
During type 1 diabetes mellitus, the hyperglycemic environment causes an 
enhanced oxidative environment, from which post-translational modification analyses 
revealed a higher number of oxidations in type 1 diabetic IFM, compared to type 2 
diabetic SSM. This enhanced oxidative environment is a result of increased ROS 
production that damages important proteins and subsequent processes that are 
required for proper mitochondrial function. Along with a higher membrane potential, IFM 
have higher respiration and protein import rates compared to SSM. Because of these 
characteristics, type 1 diabetic IFM produce higher levels of ROS; and consequently, 
are impacted to a greater extent than SSM. Although the reported decrease in 
cardiolipin content in type 1 diabetic IFM could also be caused by the oxidative 
environment, data reported in chapter 2 indicated that an important constituent required 
for cardiolipin biosynthesis was significantly decreased; therefore, the enhanced 
oxidative environment could be the underlying mechanism contributing to the defective 
biosynthesis of cardiolipin. To identify the mechanism contributing to decreased 
cardiolipin content, we first evaluated the biosynthetic pathway of cardiolipin during a 
type 1 diabetic insult (Chapter 2). 
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The cardiolipin biosynthetic pathway is a multi-step process that requires many 
enzymatic reactions to occur in order for the mature form of cardiolipin to be produced 
(Figures 1.4 and 2.1) (26, 27). We hypothesized that at least one of the reactions 
involved in this pathway was affected by type 1 diabetes mellitus. The mRNA and 
protein levels of the enzymes directly responsible for the synthesis of cardiolipin were 
analyzed and results indicated that none of the mRNA levels were altered in the diabetic 
heart; and interestingly, only one protein was significantly decreased in the type 1 
diabetic IFM – CRLS (Table 2.1 and Figure 2.2). Because the protein content of CRLS 
was decreased, we next analyzed its activity and found that CRLS activity was 
significantly decreased in the type 1 diabetic IFM (Figure 2.3). These results taken 
together suggest that the main contributors to the loss of cardiolipin content during both 
type 1 and type 2 diabetes mellitus is decreased CRLS content and activity. 
 
 Housed in the IMM, the oxidative phosphorylation machinery requires an 
association with cardiolipin to function properly (Figure 1.2) (11, 12, 27, 29). In both the 
type 1 and type 2 diabetic mouse model, data produced from our laboratory indicated 
decreased ETC complex activity for complexes I, III, IV and V in the diabetic IFM and 
diabetic SSM, respectively (Figure 2.4) (8, 9). Similarly in the type 2 diabetic human 
heart model, ETC complex I and IV activities, as well as the protein expression of the 
aforementioned complexes were decreased (Figures 3.4, 3.6 and 3.7). Data reported in 
chapter 2 revealed decreased associations between cardiolipin and ATP synthase 
subunits in the presence of a type 1 diabetic insult (Figure 2.6); therefore, one potential 
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mechanism contributing to the decreased ETC complex activities may be the decrease 
in cardiolipin content.  
 
 The dysfunctional ETC complexes can further negatively impact the IMM through 
different pathways. First, the IMM is the primary source of ROS production, specifically 
at ETC complex I and complex III (21); therefore, defective ETC complexes I and III 
could cause an increase in ROS, which would further inhibit proper mitochondrial 
function. For example, an increase in ROS can enhance the oxidative environment of 
mitochondria causing stress to the organelle and its functional processes. Also, an 
increase in ROS can target the double bonds composing tetralinoleic cardiolipin (Figure 
1.3). This alteration in cardiolipin composition can negatively impact the interactions 
between the lipid environment and important associated proteins, rendering IMM 
proteins, such as ETC complexes, dysfunctional. With a lower cardiolipin content 
already present during a diabetic insult, alterations to the remaining lipid environment 
could severely damage cardiac mitochondria. Secondly, if the ETC complexes do not 
function properly during a diabetic insult, ATP production may decrease, causing 
mitochondrial dysfunction and ultimately, cardiac contractile dysfunction. Taken all 
together, the results suggest possible mechanisms underlying the decreased ETC 
complex activities, all of which are deleterious effects of diabetes mellitus to the IMM.  
  
Processes housed within the IMM also require a proper membrane potential 
which is generated by the IMM. Cardiolipin plays a role in membrane stability (27); and 
therefore, in the maintenance of the membrane potential. Because the content of 
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cardiolipin is decreased during a diabetic insult, the membrane potential becomes 
unstable. Using mouse models, we have previously reported decreased membrane 
potential in type 1 diabetic IFM (9), as well as in type 2 diabetic SSM (8). This decrease 
in membrane potential negatively impacts the processes that are located within the 
IMM, such as oxidative phosphorylation and protein import. 
 
 Glucose – mediated and fatty acid – mediated respiration were both decreased in 
SSM of type 2 diabetic human atrial tissue, with no change observed in IFM (Chapter 
3). These data are in partial agreement with those data that we reported previously in 
the db/db mouse heart (8). In a type 1 diabetic mouse model, state 3 mitochondrial 
respiration was also reported to be decreased specifically in IFM (9). Because 
mitochondrial respiration relies on a membrane potential, this decrease observed in 
mitochondrial respiration could be attributed in part to the decreased membrane 
potential in type 1 diabetic IFM and type 2 diabetic SSM. 
 
 As depicted in Figure 1.2, the protein import machinery also resides in the IMM 
and is known to interact with cardiolipin (19, 32). Both protein import activity and a key 
constituent involved in the protein import process, Grp75, have been reported to be 
decreased during type 1 diabetes mellitus (3). In type 2 diabetic human atrial tissue, 
preliminary data examining protein import revealed decreased protein import rates in 
diabetic SSM compared to a non-diabetic heart, with no effect on IFM (Figure 6.4). 
Grp75 protein content was also decreased in human type 2 diabetic SSM (Figure 6.3). 
The influence of diabetes on protein import and Grp75 protein levels could be altered 
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due to a number of reasons. First, cardiolipin is known to be associated with the protein 
import machinery (19, 32) and the decrease in cardiolipin content could subsequently 
contribute to the loss in protein import activity (Chapter 2). Secondly, a loss of Grp75 
protein content could either be a result of or a mechanism contributing to the decreased 
protein import (Chapter 6) (3, 8). Because decreased protein import is a critical 
contributor to diabetic-associated mitochondrial dysfunction, a novel transgenic mouse 
line overexpressing Grp75 was generated in our laboratory (Figure 6.1).  
  
 To ensure that the Grp75 overexpressing transgenic mouse was in fact 
overexpressing Grp75, we co-incubated mitochondrial subpopulations from a control 
and a transgenic mouse with MitoTracker Deep Red 633, which specifically stain 
respiring mitochondria, along with a Grp75-PE conjugated antibody. We subjected the 
co-stained mitochondria to flow cytometry, which was able to detect the mitochondria 
stained with both MitoTracker Deep Red 633 and Grp75-PE, since each dye used a 
different laser to emit fluorescence. Table 6.1 depicted the results of Grp75 over-
expression between a control mouse and a transgenic mouse as measured by the 
mean fluorescence intensity, from which we concluded that the Grp75 mouse 
overexpressed Grp75 compared to its control counterpart.  
 
An additional method to measure Grp75 overexpression would be to perform a 
Western blot; however, if Grp75 overexpression increased protein import, then the 
Western blot can no longer be loaded per mitochondrial protein content because the 
amount of protein between control and the transgenic mouse would more than likely not 
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be equal. Therefore, the amount of intact mitochondria in each isolated sample could be 
measured by selectively staining for intact mitochondria and subjecting the mitochondria 
to flow cytometry (9, 34). A Western blot could then be loaded per intact mitochondria; 
however, the isolated mitochondrial sample would contain not only intact mitochondria, 
but also debris; therefore, without separating the debris, a Western blot would not truly 
depict the amount of Grp75 protein in the overexpressing transgenic mouse. Because of 
these limitations, analyzing the mean fluorescence intensity of co-stained mitochondrial 
sub-populations represented the most accurate overexpression measurement. 
  
Once the overexpression of Grp75 was established, the therapeutic benefit of 
overexpressing GRP75 on mitochondrial function during a diabetic insult was evaluated. 
Mitochondrial respiration is decreased in IFM during a type 1 diabetic insult (9); 
however, in the presence of Grp75 overexpression, state 3 mitochondrial respiration 
was restored in diabetic IFM, as seen in Figure 6.2, with no effect on state 4 or SSM. 
Taken together, the preliminary data collected demonstrated that the overexpression of 
Grp75 has the ability to provide cardioprotection in the presence of diabetes mellitus. In 
order to fully determine the therapeutic advantage to overexpressing Grp75, cardiac 
functional analyses and further mitochondrial experimentation, including protein import, 
is warranted.  
 
Table 4.1 lists the reported deleterious effects to mitochondrial subpopulation 
function observed during diabetes mellitus. Taken together, the mitochondrion is 
negatively impacted by diabetes mellitus regardless of the type of diabetes mellitus or 
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the mitochondrial subpopulation affected. This negative impact leads to deleterious 
effects to the IMM and compromising the proteins associated with the lipid environment, 
specifically cardiolipin. Decreased protein import could be contributing to the loss of the 
CRLS protein, from which cardiolipin content are reduced. This reduction in cardiolipin 
content contributes to the dysfunctional processes housed within the IMM, including 
decreased oxidative phosphorylation, as well as further exacerbation of protein import 
activity. Genetic manipulation of Grp75 provided protection against diabetes-associated 
mitochondrial dysfunction, possibly by preserving the IMM through restored cardiolipin 
synthase protein levels and consequently, cardiolipin content. This restoration in 
cardiolipin content would preserve cardiolipin-IMM protein associations, as well as key 
processes required for proper mitochondrial function; however, further studies are 
warranted. The preliminary data gathered from evaluating the overexpression of Grp75 
may lend insight to a possible therapeutic target to alleviate the detrimental effects of 
diabetes mellitus on mitochondrial function. Further, because an increase in the 
oxidative environment during type 1 diabetes mellitus has been previously reported (2), 
another possible beneficial treatment could be developed by targeting the antioxidant 
capacity of mitochondria and inhibiting the increased oxidative environment during type 
1 diabetes mellitus. Potential therapeutic strategies are further discussed in Chapter 5. 
Nonetheless, the damage to the IMM signifies the importance of preserving the IMM by 
developing therapeutic strategies aimed at relieving mitochondrial dysfunction.  
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Table 4.1. Mitochondrial dysfunction associated with type 1 and type 2 diabetes 
mellitus in mouse and human models. 
 
 Type 1 diabetic 
mouse (STZ) 
Type 2 diabetic 
mouse (db/db) 
Type 2 diabetic 
human 
 SSM IFM SSM IFM SSM IFM 
State 3 Respiration (G:M) - ↓# ↓ - ↓ - 
State 4 Respiration (G:M) - N/A - - ↓ - 
State 3 Respiration (PC:M) N/A N/A ↓ - ↓ - 
State 4 Respiration (PC:M) N/A N/A ↓ - ↓ - 
ETC Complex I - ↓ ↓ - ↓ - 
ETC Complex III - ↓ ↓ - - - 
ETC Complex IV - ↓ ↓ - ↓ - 
ETC Complex V - ↓ ↓ - - - 
Cardiolipin content - ↓ N/A N/A ↓$* - 
Tetralinoleic cardiolipin content - ↓ N/A N/A N/A N/A 
Cardiolipin-key protein associations - ↓ N/A N/A N/A N/A 
Protein import - ↓ N/A N/A ↓* -* 
Grp75 content - ↓ ↓ - ↓ - 
 
*Indicates preliminary data; - indicates no change; N/A indicates not measured; $ indicates a decrease 
trend; and # represents preliminary restoration in the presence of Grp75 overexpression. Data collected 
from our laboratory. 
  
In conclusion, our data exemplifies the importance of recognizing that most of the 
processes and subsequent proteins affected during both type 1 and type 2 diabetes 
mellitus are housed within the IMM, suggesting that the IMM is targeted by diabetes 
mellitus. Further,  the data collected from examining mitochondrial dysfunction during a 
type 1 and type 2 diabetic insult provides evidence for the importance of examining the 
two mitochondrial subpopulations separately because the effects of each type of 
diabetes mellitus impacts the mitochondrial subpopulations oppositely. The results of 
this dissertation are in agreement with the hypothesis in that the mitochondrion is 
negatively impacted by diabetes mellitus, leading to deleterious effects to the IMM and 
compromising the proteins associated with cardiolipin and protein import, which 
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translates to the diabetic human heart. The results of the studies in this dissertation 
establish the importance preserving the IMM and those processes contained within to 
alleviate mitochondrial dysfunction associated with the diabetic heart. 
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FUTURE DIRECTIONS 
 
 Research has established an association between mitochondrial dysfunction and 
the type 2 diabetic heart (2-4); however, the lipid environment, lipid-protein associations, 
and specific processes contained within have not yet been examined in diabetic 
mitochondrial subpopulations. Future studies examining the IMM phospholipid 
environment in a mouse model of type 2 diabetes mellitus, specifically cardiolipin and 
cardiolipin remodeling, would advance the understanding of the environment and the 
protein interactions within, which are required for proper mitochondrial function. 
Preliminary data collected for the studies included in this dissertation determined lower 
cardiolipin content in type 2 diabetic SSM from human atrial tissue, which was gathered 
from high performance thin layer chromatography and iodine vapor staining. A more 
accurate method employing mass spectrometry would more efficiently measure the 
levels of total cardiolipin content, as well as the levels of different cardiolipin species. 
Data reported in chapter 2 revealed decreased interactions between cardiolipin and 
ATP synthase subunits in a type 1 diabetic mouse model, specifically in IFM. These 
interactions could also be measured during a type 2 diabetic insult, as well as the 
interactions between cardiolipin and other proteins housed in the IMM. Together, these 
results could potentially lend insight as to why some of the proteomic alterations 
observed during a type 2 diabetic insult (4) may be occurring. 
 
 After revealing the negative impact of type 2 diabetes mellitus on the SSM in 
human atrial tissue (Chapter 3), alterations in the mitochondrial proteome should be 
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further examined. Chapter 3 included data that reported decreased ETC complex I and 
IV activities in type 2 diabetic SSM. The underlying mechanism causing this decrease in 
ETC complex I and IV activities was determined to be decreased protein expression of 
ETC complex I and IV. Although this measurement included the ETC complex as a 
whole unit, individual subunits are also more than likely affected by a type 2 diabetic 
insult; therefore, this finding warrants further experimentation examining alterations in 
the mitochondrial proteomic makeup during type 2 diabetes mellitus. 
 
 Preserving the IMM can be accomplished by focusing on different proteins or 
processes located within the IMM. For example, during diabetes mellitus, mitochondrial 
membrane potential is decreased and in conjunction with a disruption of the lipid 
environment, specifically cardiolipin, a preservation strategy targeting the structure and 
integrity of the IMM could prove to be beneficial in protecting mitochondrial function. 
This could be through genetic manipulation of structural proteins that are altered in the 
presence of diabetes mellitus. In order to conserve the IMM integrity, another strategy 
could target the phospholipid environment. 
 
 Total cardiolipin content was lower in SSM of type 2 diabetic human atrial tissue 
(Chapter 3), and significantly decreased in IFM of type 1 diabetic mouse hearts 
(Chapter 2) along with tetralinoleic cardiolipin (5). The data in chapter 2 also revealed 
decreased CRLS protein content and activity, which suggested that the decrease in 
cardiolipin was due to deficient cardiolipin biosynthesis at the level of CRLS. In order to 
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restore cardiolipin content, our laboratory created a genetically modified mouse model 
that overexpressed CRLS (Figure 5.1). 
 
 A.                  Vector Map 
 
B.                    RT-PCR 
  
 
Figure 5.1. CRLS pCAGGS vector map.  (A) Map of CLS transgenic construct using 
pCAGGS.  Utilization of this vector provides high levels of protein expression. (B) Real 
time PCR amplification plot using a custom designed probe which amplifies the CMV 
region of the CLS construct. 
 
The CRLS construct was placed under the control of the human cytomegalovirus 
immediate-early enhancer and chicken β-actin promoter with first intron. This vector 
allows for high levels of protein expression (9) in all tissues, which would be beneficial 
for studies using heart, skeletal or liver tissue (8). Interestingly, Kiebish et al. also 
developed a mouse line that overexpressed CRLS; however, the transgene was heart 
specific (7). Although Kiebish et al. did not show restored total cardiolipin levels during a 
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type 1 diabetic insult as one would expect, the authors determined that tetralineolic 
cardiolipin levels were restored back to normal levels, which ultimately attenuated the 
mitochondrial dysfunction associated with type 1 diabetes mellitus. 
  
Because CRLS is nuclear-encoded, another strategy that could potentially result 
in increased CRLS protein content is to increase protein import rates. During type 1 
diabetes mellitus, protein import rates are decreased, specifically in the diabetic IFM. By 
restoring protein import rates, more CRLS could enter mitochondria and potentially 
improve cardiolipin content, ultimately preserving mitochondrial function. By utilizing the 
novel transgenic mouse line described in this dissertation (Chapter 4), future studies 
can examine the therapeutic benefit of Grp75 overexpression on protein import rates to 
determine if the import rates are rescued, which in turn could restore CRLS and other 
proteins altered during a type 1 diabetic insult. 
  
Increased ROS production is the main contributor to mitochondrial dysfunction 
associated with diabetes mellitus; therefore, prevention of an enhanced oxidative 
environment may lead to preservation of the IMM. For example, animal models 
manipulated to overexpress players involved in the antioxidant defense system, such as 
manganese superoxide dismutase, have provided protection against mitochondrial 
dysfunction associated with diabetes mellitus (10). Our laboratory recently reported that 
overexpression of mitochondrial phospholipid hydroperoxide glutathione peroxidase, 
which is involved in the antioxidant defense system of mitochondria, restores 
mitochondrial function during type 1 diabetes mellitus through scavenging lipid 
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hydroperoxides (1). This model specifically could also be beneficial to the cardiolipin 
environment within the IMM, by potentially restoring cardiolipin levels and ultimately, 
mitochondrial function during diabetes mellitus. 
 
  Other than cardiolipin, phospholipid alterations to phospholipids housed within in 
the IMM could restore functionality to a damaged IMM. For example, cardiac 
mitochondrial PG content has also shown to be decreased during type 1 diabetes 
mellitus (6). By creating a transgenic mouse line that overexpresses a constituent in the 
biosynthetic pathway of PG, the decreased PG content may be restored. Not only would 
this restoration aid in the preservation of the IMM, but PG, along with CDP-DAG, is also 
hydrolyzed by CRLS to produce cardiolipin; therefore, cardiolipin levels could also be 
restored. Other phospholipids housed within the IMM include, but are not limited to, 
phosphatidylcholine, phosphatidylserine, and phosphatidyl-ethanolamine. If damaged 
during diabetes mellitus, restoration of any of the phospholipids that compose the IMM 
would be beneficial to the IMM environment and subsequent function. 
 
 The goal of this dissertation was to evaluate the impact of type 1 diabetes 
mellitus on the IMM phospholipid environment, specifically cardiolipin, and the 
processes that are housed within. The overall conclusion highlighted the importance of 
preserving the IMM; therefore, future directions should focus on this preservation 
through further examination of the impact of diabetes mellitus to the mitochondrial 
proteome and processes, in order to attenuate the mitochondrial dysfunction that is 
associated with diabetes mellitus. 
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Figure 6.1 
 
A.      Grp75 Transgenic construct B.    Real time PCR amplification plot 
  
C.                 Grp75 PCR blot  
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Figure 6.1. Grp75 vector map.  (A.) Map of GRP75 transgenic construct housed in a 
pCAGGS vector.  (B.)  Real time PCR amplification plot using a custom designed probe 
which amplifies the CMV region of the Grp75 construct. (C.) PCR analysis was also 
performed to confirm transgene presence in positive mice. N = 2.   
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Figure 6.2 
A.                                       SSM   
 
 
 
 
B.                                        IFM 
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Figure 6.2. The protective benefit of Grp75 overexpression on mitochondrial 
respiration. Mitochondria respiration measured in isolated mitochondria from wild-type 
control (WT Ctrl), Grp75 transgenic control (TG Ctrl), wild-type diabetic (WT Diab) and 
transgenic diabetic (TG Diab).  (A.) SSM state 3 and state 4 respiration measured in all 
four groups. (B.) IFM state 3 and state 4 respiration measured in all four groups. Key is 
included. Values are presented as means ± SEM; *P < 0.05 WT Diab vs WT Ctrl. #P < 
0.05 WT Diab vs TG Diab; N = 7 control wild-type control, 6 Grp75 transgenic, 9 wild-
type diabetic and 6 transgenic diabetic. 
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Figure 6.3 
 
A.                          SSM B.                           IFM 
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Figure 6.3. Protein levels of Grp75 in the type 2 diabetic human heart. Western blot 
analysis of protein import constituent Grp75 in non-diabetic and diabetic human heart 
tissue. (A.) Representation of Grp75 protein content in SSM and in (B.) IFM. Control for 
protein loading was confirmed by COXIV. Values are presented as means ± SEM; *P < 
0.05 Non-diabetic vs. diabetic; N = 4. 
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Figure 6.4 
 
A.                          SSM B.                             IFM 
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Figure 6.4. Preliminary protein import in the type 2 diabetic human heart. (A.) 
Protein import rates between non-diabetic and diabetic human SSM. (B.) Protein import 
rates between non-diabetic and diabetic human IFM. Values are presented as percent 
of control. N = 1. 
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Figure 6.5 
 
A.                          SSM B.                             IFM 
 
 
 
 
  
 
  
P = 0.1 
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Figure 6.5. Cardiolipin content in the type 2 diabetic heart. High performance thin 
layer chromatography of cardiolipin content in isolated mitochondrial subpopulations of 
non-diabetics and type 2 diabetic patients. (A.) Representation of cardiolipin content in 
SSM and in (B.) IFM. Values are presented as means ± SEM. Two spots represent one 
sample; N = 3. 
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Table 6.1 
 
 
Mean Fluorescence 
Intensity 
SSM  
Control  36.77 
Transgenic Grp75  39.41 
IFM 
Control  42.42 
Transgenic Grp75  45.92 
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Table 6.1. Grp75 overexpression in isolated mitochondrial subpopulations. 
Mitochondrial subpopulations were incubated with MitoTracker Deep Red 633 and 
Grp75-PE and subjected to flow cytometry. Mitochondria that were co-stained with both 
dyes were analyzed. The control mean fluorescence intensity was compared to the 
transgenic mean fluorescence intensity for each subpopulation. N = 1. 
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